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1Le syndrome des anticorps antiphospholipides a été décrit en 1983. Il s’agit d’une
maladie auto-immune caractérisée par des taux élevés d’anticorps antiphospholipides
(APLA) associés à des thromboses (veineuses ou artérielles) et/ou à des pertes fœtales à
répétition (International Consensus Statement for Definite Antiphospholipid Syndrome).
Le syndrome des anticorps antiphospholipides peut se manifester de manière isolée ou
accompagner d’autres pathologies, en particulier des maladies auto-immunes comme le
lupus érythémateux systémique.
Plusieurs études ont montré que les APLA sont capables d'activer les cellules
endothéliales (CE) in vitro. Les mécanismes liés à cette activation sont un des sujets de
recherche de la Division d’Angiologie et d’Hémostase. Il a été observé qu’un anticorps
monoclonal reconnaît un phospholipide anionique nommé acide lysobisphosphatidique
(Kobayashi et al, 1998; Galve-de Rochemonteix et al, 2000). Les études suivantes ont
montré que l’acide lysobisphosphatidique est une cible importante pour les APLA, et que
les APLA s’accumulent dans les endosomes tardifs des CE isolées des veines ombilicales
en redistribuant l’insulin-like growth factor 2/ mannose-6-phosphate receptor (CI-M6PR)
de l’appareil de Golgi aux endosomes tardifs. De manière concomitante, il a été découvert
que la beta2 glycoprotéine I (β 2GPI) s’accumule sur la surface cellulaire des endosomes
tardifs et modifie le trafic des protéines intracellulaires. Ceci a en particulier été démontré
par la redistribution du CI-M6PR de l’appareil de Golgi à l’intérieur des endosomes tardifs
(Dunoyer-Geindre et al, 2001).
Les mécanismes par lesquels les APLA induisent un phénotype thrombotique ont
également été étudiés dans la Division. Nous avons observé que l’incubation des CE avec
des anticorps anti-β 2GPI provoque la redistribution du facteur de transcription nucléaire
kB (NFkB) du cytoplasme dans le noyau (Dunoyer-Geindre et al, 2002). Cette
redistribution du NFkB est importante pour l’activation des CE et est accompagnée d’une
augmentation de l’expression du facteur tissulaire et des molécules d'adhésion
leucocytaires ICAM-1, VCAM-1 et E-sélectine (Dunoyer-Geindre et al, 2002). Des études
récentes ont montré que l’activation des CE par les APLA provoque un phénotype
endothélial pro-inflammatoire accompagné d’une adhésion des monocytes à l’endothélium
et par la suite une pénétration dans le sous-endothélium (Pierangeli et al, 2000). D’autres
2études ont mis en évidence une corrélation entre l’augmentation des molécules d’adhésion
par certains anticorps monoclonaux anti-β 2GPI et la résorption fœtale observée chez des
souris (George et al, 1998).
Notre travail a porté principalement sur l’effet des statines sur les changements des
CE lorsqu’elles sont incubées avec du TNF ou des APLA. Notre hypothèse était que les
patients avec APLA pourraient bénéficier d’un traitement par les statines. En effet ces
médicaments ont de nombreuses autres actions que la seule inhibition de la biosynthèse du
cholestérol. Ces effets dits pleiotropiques pourraient expliquer également leurs effets
cliniques bénéfiques sur la régression des lésions athérosclérotiques et sur la réduction des
complications cardiovasculaires (Scandinavian Study group, 1994; Hebert, 1997). Nous
avons cherché à voir si in vitro l’ajout de statines permettait de diminuer le phénotype pro-
inflammatoire des CE incubées avec du TNF ou des APLA.  De manière inattendue, nous
avons observé que les statines augmentaient l'effet des APLA ou du TNF sur l'expression
des molécules d'adhésion. Nous avons ensuite étudié les mécanismes pouvant expliquer cet
effet. Nous avons pu démontrer que l’effet des statines était bloqué par une co-incubation
avec le mévalonate ou le geranylgeranyl pyrophosphate et mimé par le GGTI-286, un
inhibiteur de la geranylgeranyl transférase.
En résumé nos résultats montrent que l'effet des APLA sur les cellules
endothéliales in vitro est augmenté par les statines et que l'effet des statines est dû à des
modifications de protéines geranylgeranylées.
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6ABBREVATIONS
ACA anticardiolipin antibodies
APC activated protein C
APC-R activated protein C resistance
APLA antiphospholipid antibodies
APS antiphospholipid syndrome
aPTT activated partial thromboplastin time
β 2GPI beta2 glycoprotein I
CAM cell adhesion molecules
CI-M6PR cation-independent mannose-6-phosphate receptor
CL cardiolipin
CRP C-reactive protein
dPT dilute prothrombin time
dRVVT dilute Russell’s viper venom time
EC endothelial cells
EDRF endothelium-derived relaxing factor
EGF epidermal growth factor
ELISA enzyme-linked immunosorbent assay
eNOS endothelial nitric oxide synthase
ET-1 endothelin-1
FCS foetal calf serum
FPP farnesylpyrophosphate
FTase farnesyltransferase
FTI-277 farnesyltransferase inhibitor-277
GGPP geranylgeranylpyrophosphate
GGTase geranylgeranyltransferase
GGTI-286 geranylgeranyltransferase inhibitor-286
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A
HRP horseradish peroxidase
HSVEC human saphenous vein cells
7HUVEC human umbilical vascular endothelial cells
INR international normalized ratio
KCT kaolin clotting time
LA lupus anticoagulant antibodies
LFA-1 β2 integrin function antigen-1
MCP-1 monocyte chemoattractant protein-1
MHC major histocompatibility complex
MMP matrix metalloprotease
NFkB nuclear factor kB
NO nitric oxide
OPD o-phenylenediamine dihydrochloride
PA phosphatidic acid
PAI-I plasminogen activator inhibitor type I
PC phosphatidylcholine
PE phospatidylethanolamine
PGI 2 prostacyclin
PI phosphatidylinositol
PL phospholipid
PS phosphatidylserine
Pt prothrombin
SMC smooth muscle cells
SLE systemic lupus erythematosus
TAT thrombin-antithrombin complexes
TM thrombomodulin
vWF von Willebrand factor
8SUMMARY
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the
persistent presence of antiphospholipid antibodies (APLA) associated with venous and
arterial thrombosis as well as foetal loss. APLA constitute a heterogeneous family of
antibodies which play a pathogenic role rather than just being a diagnostic marker of APS.
The thrombophilic state has been partially related to the interactions of APLA with
endothelial cells (EC). Due to their multiple properties on EC and the numerous favourable
clinical trials, the use of statins has also been advocated for patients with APS. Indeed,
besides their cholesterol-lowering activity, statins may influence several events in the
vessel wall by blocking the mevalonate synthesis and inhibiting the production of down-
stream metabolites, such as geranylgeranylpyrophosphate (GGPP) and
farnesylpyrophosphate (FPP), that play a major role in the intracellular modification of
important signaling proteins as Rho and Ras.
In this study we investigated whether adhesion molecule expression induced by
APLA on EC is influenced by various statins, namely simvastatin, fluvastatin and
pravastatin. The effect of APLA was compared with TNF-α and LPS. Contrary to what
could be expected, we consistently found in our experimental conditions that pretreatment
with statins potentiated the APLA-induced expression of E-selectin and VCAM-1 on EC.
Mevalonate reversed the potentiating effect of these statins. Studying further the
mechanism of these effects of statins revealed that GGPP also reversed the potentiating
effect of simvastatin or fluvastatin on adhesion molecule expression, while FPP only
partially reversed this effect. Furthermore, we observed that the specific
geranylgeranyltransferase inhibitor GGTI-286, but not the farnesyltransferase inhibitor
FTI-277, mimicked the effect of simvastatin and fluvastatin by increasing the TNF-α and
APLA mediated overexpression of E-selectin and VCAM-1.
In conclusion, statins increase E-selectin- and VCAM-1-induced expression on
vascular endothelial cells stimulated with antiphospholipid antibodies. The inhibition of
geranylgeranylated protein could contribute to this effect. Our data indicate that other
experimental data should be performed before giving statins to APS patients.
9PART I: THE ANTIPHOSPHOLIPID SYNDROME
I. INTRODUCTION
The antiphospholipid syndrome (APS) was first described in 1983 (Hughes). APS is an
autoimmune disorder characterized by: 1) the presence of antiphospholipid antibodies
(APLA): anticardiolipin antibodies (ACA) and/ or lupus anticoagulant antibodies (LA),
and 2) clinical complications such as a) venous and/ or arterial thrombosis, and/or b)
pregnancy morbidity (International Consensus Statement for Definite Antiphospholipid
Syndrome). The syndrome is called primary APS when it occurs without underlying
disorder and secondary APS in patients with other diseases such as auto-immune diseases,
particularly systemic lupus erythematosus, or malignant diseases. Endothelial cell (EC)
activation by APLA seems to be one of the major pathogenic mechanisms of APS. The
mechanisms underlying this activation are one of the research topics of the Division of
Angiology and Hemostasis. It was observed that a monoclonal antibody to late endosomes
recognized the anionic phospholipid lysobisphosphatidic acid (Kobayashi et al, 1998;
Galve-de Rochemonteix et al, 2000). Further investigations showed that
lysobisphosphatidic acid is an important target for APLA and that APLA accumulate in
late endosomes of human umbilical vein endothelial cells (HUVEC) leading to a
redistribution of the insulin-like growth factor 2/ mannose-6-phosphate receptor (CI-
M6PR) from the Golgi apparatus to late endosomes. It was also found that beta2
glycoprotein I (β 2GPI) accumulate at the cell surface and in late endosomes in HUVEC,
resulting in modification of intracellular protein trafficking as shown by a redistribution of
the CI-M6PR from the Golgi apparatus to late endosomes (Dunoyer-Geindre et al, 2001).
The mechanisms by which APLA induce a thrombotic phenotype were further studied in
the Division. It was found that incubation of EC with anti-β 2GPI antibodies resulted in a
redistribution of the transcription nuclear factor kB (NFkB), an essential intermediate in
the activation of EC, from the cytoplasm to the nucleus after a delay of several hours
(Dunoyer-Geindre et al, 2002). This NFkB redistribution was accompanied by an increased
expression of tissue factor (TF) and the leukocyte adhesion molecules ICAM-1, VCAM-1
and E-selectin (Dunoyer-Geindre et al, 2002).
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Other recent data reported that EC activation by APLA lead to a proinflammatory
endothelial phenotype with a monocyte adhesion to the endothelium and penetration into
the subendothelial space (Pierangeli et al, 2000). Another study showed that upregulation
of adhesion molecules by some murine monoclonal anti-β 2GPI antibodies correlated with
foetal resorption in mice (George et al, 1998).
The aim of this study was to investigate the ability of statins, specific inhibitors of
cholesterol biosynthesis with clinically proven beneficial effects such as regression of
atherosclerotic lesions and reduction of cardiovascular complications (Scandinavian Study
group, 1994; Hebert, 1997), to modify adhesion molecule expression in APLA-activated
EC and to study the underlying mechanisms.
II. ANTIGENS AND ANTIBODIES IN THE ANTIPHOSPHOLIPID SYNDROME
Antigens
Recent studies demonstrated that APLA recognize not only determinants with anionic PL
but also neutral PL as well as proteins (Table 1).
TABLE 1. Various antigens recognized by APLA
Phospholipids cardiolipin
phosphatidylserine, phosphatidylinositol
phosphatidylethanolamine, phosphatidic acid
lysobisphosphatidic acid
Proteins β2GPI
vitamin K-dependent proteins: prothrombin, protein C, protein S,
thrombomodulin
annexins: annexin V, annexin II
others
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Phospholipids (PL)
Anionic PL are essential cofactors for the blood coagulation system. APLA are supposed
to bind the phosphodiester group of negatively charged PL. The length and composition of
the polar head groups as well the saturation of the fatty acid side chains contribute to the
antigenicity (Levy et al, 1990). Possible antigenic targets of APLA on EC include
negatively charged PL such as cardiolipin, phosphatidylserine, phosphatidylinositol,
phosphatidylethanolamine, phosphatidic acid.
- Cardiolipin (CL)
CL has been most often used to study the interaction of APLA with anionic PL. The
antibodies that directly bind to CL are characterized by the presence of a larger than
average density of positively charged arginine residues in one of antigen binding loops,
which mediate the binding to the negatively charged PL.
- Phosphatidylserine (PS), phosphatidylinositol (PI)
PS and PI may be possible antigenic targets of APLA on EC. PS is a PL occurring in
abundance in the inner leaflet of the cytoplasmic membrane and is exposed to the outer
surface after cell activation or apoptosis (Mevorach et al, 1998). PS promotes the
interaction of coagulation factors. PI derivates are important mediators of cell activation.
- Phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidic acid (PA)
Zwitterionic antigens such PE and PA have also been implicated in APS (Berard et al,
1996). PL have a positively charged substituted group that interacts electronically with the
phosphodiester, thus blocking APLA access to the phosphodiester. APLA do not usually
bind the zwitterionic molecule PC, but removal of the positively charged choline group
results in the formation of negatively charged PA, which could be bound by APLA.
- Other PL antigens
Other PL can also be involved. Recently, lysobisphosphatidic acid, a lipid related
structurally to CL and present in the membranes of late endosomes, has been identified as
another immunologic target for APLA. The team of Division of Angiology and Hemostasis
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observed that APLA could react with lysobisphosphatidic acid of internal membranes of
late endosomes, resulting in accumulation of APLA in late endosomes and subsequent EC
activation (Kobayashi et al, 1998; Galve-de Rochemonteix et al, 2000, Dunoyer-Geindre et
al, 2001). The oxidation of PL may be necessary for epitopes recognition by some APLA.
Horkko et al (1997) demonstrated that many APLA bound to CL only after it had been
oxidized, but not to a reduced CL analogue that could undergo oxidation. They suggested
that the reactive groups of oxidized CL, such as aldehydes, generated during the
decomposition of oxidized polyunsaturated fatty acids, form covalent adducts with β 2GPI
(and other proteins) and that they are epitopes for APLA.
Whether this broad response of APLA indicates polyclonality or crossreactivity could not
be determined using sera as a source of antibody. It has been shown that a human
monoclonal IgM LA is able to bind to PA, PI and PS. This provided evidence for the
polyspecificity of at least some APLA (Thiagarajan et al, 1980).
Binding of APLA to PL is also influenced by the physical state of the PL. Mice immunized
with hexagonal versus lamellar phase PL are more likely to develop APLA (Rauch et al,
1990). Protein cofactors like β2GPI may shift the orientation of some PL from the lamellar
to the hexagonal phase.
Proteins
- Beta2 glycoprotein I (β2GPI)
β 2GPI, also called apolipoprotein H, is a major protein constituent of human plasma,
where its concentration is about 200 mg/L. It is the main factor for the recognition of
anionic PL by APLA.
Structure
β 2GPI is a single-chain, 5 kDa protein consisting of 326 amino acids. It contains large
numbers of Pro and Cys residues, and is highly glycosylated (Figure 1). The protein is a
member of the complement control protein or short consensus repeat (SCR) superfamily,
characterized by repeating stretches of about 60 amino acid residues, "Sushi domains",
each with a set of 16 conserved residues and 2 fully conserved disulfide bonds. It has five
repeating SCR domains. The first four homologous repeat regions consist of about 60
amino acids with 2 disulfide bonds in each domain. The fifth domain contains 80 amino
13
acids and 3 disulfide bonds. The protein binds to phospholipid membranes via the cationic
portion of its fifth SCR domain. β 2GPI has a weak affinity for anionic PL but APLA,
binding to domains I and V, increase this affinity, due to the bivalency of the antibodies
and to conformational changes induced in the β 2GPI protein.
Functions
It was found that β 2GPI interacts specifically with lipoprotein(a) and the endothelial cell
protein annexin II (Ma et al, 2000). Although the physiologic importance of β 2GPI
anticoagulant activity is still unclear, β 2GPI acts at least in vitro as an inhibitor of the
intrinsic blood coagulation pathway due to its ability to interact with negatively charged
surfaces, which in turn are necessary for the activation of factor XII (Schousboe et al,
1985). Interestingly Mori et al (1996) have shown that β 2GPI can inhibit the anticoagulant
activity of activated protein C. Thus, it remains unclear whether β 2GPI in vivo has
anticoagulant or procoagulant properties. β 2GPI has been reported to inhibit adenosine
diphosphate-mediated platelet aggregation and the prothrombinase activity of activated
platelets (Shi et al, 1993). β 2GPI binds to cells undergoing apoptosis and may be involved
in the rapid, noninflammatory clearance of these cells by phagocytes. Recent study showed
that the opsonization of apoptotic cells with anti-β 2GPI antibodies may be a
proinflammatory event, stimulating the presentation of apoptotic cell antigens by dendritic
cells. Thus, anti-β 2GPI antibodies might possibly contribute to an autoimmune response
(Rovere et al, 1999). In addition, β 2GPI binds to the cell surfaces by binding to negatively
charged molecules such as anionic PL, heparan sulfate proteoglycans and preferentially to
oxidized low density lipoproteins. This property has been proposed to be clinically relevant
providing a link between anti-β 2GPI antibodies and atherogenesis (Matsuura et al, 1998).
- Vitamin K-dependent proteins
Prothrombin (Pt)
Pt is a vitamin K-dependent glycoprotein with a molecular weight of 72 kDa. It is activated
to thrombin by the so-called “prothrombinase complex” (coagulation factors Xa, Va, and
calcium on a procoagulant PL surface) by the cleavage of two or possibly three peptide
bonds. The first proteolytic cleavage leads to fragment 1,2 and prethrombin 2, which is
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further proteolysed to thrombin. The anti-Pt antibodies may react both with Pt and its
fragment 1,2, but not with the decarboxylated molecule. Antibodies to Pt are found in 50-
90% of patients with LA (Galli et al, 1997; Kandiah et al, 1998) but their clinical relevance
is still controversial (Galli et al, 1998). Anti-Pt antibodies may inhibit the activation of Pt
into thrombin. They are therefore expected to be anticoagulant. However, Vaarala et al
(1996) found that anti-Pt antibodies were associated with a hypercoagulable state and high
levels of anti-Pt antibodies predicted a 2.5-fold increase in the risk of myocardial infarction
or cardiac death (n =106). In contrast, other investigators (Horbach et al, 1996) reported
that the presence of anti-Pt antibodies in LA positive patients (n = 60) does not increase the
risk for thrombosis.
Protein C, protein S, thrombomodulin (TM)
These proteins are components of the protein C anticoagulant pathway. In this pathway,
thrombin binds to TM and loses its ability to convert fibrinogen into fibrin. Furthermore, it
acquires the ability to activate protein C which, in the presence of PL and protein S,
degrades the coagulation factors Va and VIIIa and blocks further thrombin generation.
Deficiency of protein C and S increases the risk of venous thrombosis (Oosting et al,
1993). Pengo et al (1996) investigated 22 patients with IgG APLA and thrombosis and
found elevated levels of anti-protein C IgG and anti-protein S IgG in 18% and 55% of the
patients, respectively. Antibodies to TM were found in 30% of the patients with a LA (n =
58) and 10% of the patients (n = 200) with unexplained thrombosis (Carson et al, 2000).
- Annexins
Annexin V (human placental anticoagulant protein 1)
Annexin V is an anionic PL-binding protein, expressed by placental and vascular
endothelium. It is postulated that annexin V plays a thromboregulatory role at the vascular-
blood interface by shielding anionic PL from forming a complex with coagulation proteins
in the circulation. Annexin V could play an important role in the clinical manifestations of
APS, particularly in obstetrical complications (Rand et al, 1999; Rand et al, 2002).
Annexin II
Annexin II has not been presently implicated as a target antigen of APLA. However, it was
identified as a high affinity β 2GPI-binding protein at the surface of EC, another
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mechanism of β 2GPI endothelial cell binding being through the putative PL-binding site
located in the fifth domain of the molecule (Meroni et al, 2001). Annexin II does not span
the cell membrane, its involvement probably requires an unknown adapter protein (Ma et
al, 2000).
- Other proteins
Other potential protein targets for APLA include various proteins such as factor X, high
molecular weight kininogen, factor XI, and the protein core of heparan sulfate (Shibata et
al, 1994).
In summary, different antigens have been identified in APS. It is now known that antigen
targets are mainly proteins such as β 2GPI, Pt or TM forming eventually a complex with
various phospholipids.
Antibodies
APLA comprise a broad family of autoantibodies that includes both LA, detected by
coagulation tests, and ACA, detected by ELISA methods (Pierangeli et al, 2001).
Immunoglobulin classes
Previous data have shown that the strongest associations of ACA and anti-β 2GPI
antibodies with clinical manifestations of APS involve antibodies of the IgG isotype.
Cohen et al (1993) determined in vivo that immunisation of mice with pathogenic IgG and
IgM ACA, isolated from the serum of a patient with APS, induce the production by the
mice of anti-ACA with ACA activity. The mice developed overt APS. IgG ACA were
found to have higher pathogenic potential than IgM ACA. However, several works suggest
that IgM as well as IgA may also be associated with the disease, although to a lesser
extent. Anti-β 2GPI antibodies of IgG, A, and M classes have been reported in 84.8%,
59.3% and 51.5% of patients with primary APS, respectively (Lacos et al, 1999). Amoroso
et al (2003) evaluated the prevalence of IgG and IgM antibodies to various antigens in sera
from 87 patients affected by SLE. IgG ACA, IgG anti-PA, IgG anti-PI, IgG anti-PS, and
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IgG anti-β 2GPI were found in 53%, 37%, 32%, 38%, and 24% of patients, respectively.
IgM-ACA, IgM anti-PA, IgM anti-PI, IgM anti-PS, and IgM anti-β 2GPI were detected in
15%, 17%, 18%, 14%, and 16%, respectively.
- IgG
The association of thrombotic risk with high-titer IgG ACA or anti-β 2GPI antibodies,
often together with LA, has been confirmed in several studies (Gattorno et al, 1995; Silver
et al, 1996). Sammaritano et al (1997) investigated whether the presence of ACA of a
specific IgG subclass is associated with clinical complications of APS. They found that
IgG2 was the predominant subclass of ACA, detected in 75% of the patients, and it was
significantly associated with thrombotic complications. The IgG subclass distribution of
anti-β 2GPI and ACA in patients with primary APS and secondary APS was studied
recently (Samarkos et al, 2001). Mean values for anti-β 2GPI antibodies were as follows:
IgG1– 24.4%, IgG2– 70.2%, IgG3– 5.0%, IgG4– 0.4%. The reported IgG subclass
distribution for ACA was: IgG1– 40.1%, IgG2– 32.8%, IgG3– 23.7%, IgG4– 3.3%.
Comparing the ranking of IgG subclasses of anti-β 2GPI antibodies (IgG2 >IgG1 >IgG3
>IgG4 ) and ACA (IgG1 >IgG2 >IgG3 >IgG4 ), IgG2 was the most prevalent subclass for
anti-β 2GPI antibodies whereas for anti-CL antibodies IgG1, IgG2 and IgG3 were all
frequently elevated. An association between IgG2 and IgG3 anti-β 2GPI antibodies and
venous thrombosis has been shown, while IgG2 and IgG3  ACA were found to be more
specifically associated with arterial thrombosis.
- IgM
In a study determining the distribution of ACA in primary and secondary APS, IgM were
found in 26% of secondary APS cases and in 15.8% of primary APS group (Vianna et al,
1994). The antibodies of IgM isotype were related mainly to thrombocytopenia and heart
valve disease (Diri et al, 1999). APLA, associated with infections, typically are IgM
isotypes and are usually transient (Jaeger et al, 1992).
- IgA
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Evidence that IgA antibodies may be important continues to accumulate (Lacos et al,
1999). A significant relationship has been demonstrated between increased IgA levels and
a history of venous thrombosis, thrombocytopenia, heart valve disease, livedo reticularis,
and epilepsy. Interestingly, black patients with primary and secondary APS appear to have
a higher frequency of IgA anti-β 2GPI antibodies, suggesting genetic predisposition for
these antibodies (Diri et al, 1999).
- Coexistence of different classes of APLA in the same patient
It has been recently reported that the concurrent presence of IgG, IgM, and IgA appears to
increase the frequency of recurrent spontaneous abortions as compared with the presence
of a single isotype among the autoantibodies (Guglielmone et al, 1999). Vogel et al (1991)
determined APLA in an unselected group of 63 SLE patients. They found APLA in 50.8%
of the patients and the simultaneous presence of LA and ACA was associated with an
increased of arterial thromboembolic events.
In summary, various studies have demonstrated that APLA are a large and heterogeneous
family of immunoglobulins from IgG, IgM, and IgA classes and that the simultaneous
presence of APLA increases the risk of clinical complications.
III. LABORATORY DETECTION OF APLA
History
In 1952, Conley and Hartmann published the first description of two patients with SLE and
an unique PL-dependent coagulation inhibitor characterized by prolongation of the whole
blood clotting time and the prothrombin time. Both patients had a biologic false-positive
serological test for syphilis with no evidence of infection. The antibodies responsible for
the false-positive serological test for syphilis were ultimately found to recognize CL within
the test reagent. In subsequent years, several authors described similar inhibitors that
interfered with prothrombin time activation, but without specificity to any known
coagulation factors; a number of these patients also had false-positive serological test for
syphilis (reviewed in Shapiro et al, 1982). In 1957, Laurell and Nilsson described an
association between chronic biologically false-positive serological test for syphilis, a
circulating anticoagulant, and recurrent pregnancy loss. A paradoxal association between
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PL-dependent coagulation inhibitors and thrombosis was first recognized by Bowie et al in
1964. They described the presence of thrombotic complications in 4 of 8 SLE patients
having this inhibitor. The term «lupus anticoagulant» (LA) was proposed in 1972 to
describe these inhibitors on the basis of their prevalence in SLE patients (Feinstein et al,
1972). In 1980, the immunologic nature of interaction of LA with anionic PL was
demonstrated by isolating an IgM paraprotein with LA activity from a patient with
macroglobulinemia (Thiagarajan et al, 1980). This paraprotein inhibited the Ca2+ -
dependent binding of prothrombin and factor X to PS-containing liposomes, explaining the
extremely prolonged PL-dependent coagulation tests seen in the patient. This paraprotein
did not interfere with the binding of factor Xa to platelets, suggesting an explanation for
the fact that this patient, like most patients with LA, had no bleeding tendency.
Subsequently, it was observed that most LA reacted with CL, which was used as the
antigen in serologic tests for syphilis (Pengo et al, 1987). Based on these observations, in
1983 Harris et al developed a radioimmunoassay and, subsequently an ELISA for ACA
demonstrating the overlapping specificity of LA, ACA and other APLA.
The complex specificity of ACA became apparent in 1990 when several groups found that
actually the majority of ACA in ELISA required the presence of a plasma protein, β 2GPI,
in addition to anionic PL (Bevers et al, 1991; Galli et al, 1991; Koike et al, 1991).
Subsequently, antibodies to a number of PL-plasma protein complexes have been
described, involving among others prothrombin, protein C and annexin V, all binding to
anionic PL.
Actual laboratory and clinical criteria for APS were formulated during the workshop in
Sapporo, 1998, following the Eigth International Symposium on APLA.
Laboratory criteria for APS
Definite APS is considered to be present in a given patient when at least one of the clinical
criteria (see chapter IV) and at least one of the main following laboratory criteria are met:
A) ACA of IgG and/or IgM isotype in blood, present in medium or high titer, on 2 or more
occasions, at least 6 weeks apart, measured by a standardised ELISA for β 2GPI-dependent
ACA,
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B) LA present in plasma on 2 or more occasions at least 6 weeks apart, detected according
to the guidelines of the International Society of Thrombosis and Hemostasis (Scientific
Subcommittee on Lupus Anticoagulants/ Phospholipid-Dependent Antibodies, 1995), in
the following steps (Figure 2):
1. Prolonged PL-dependent coagulation demonstrated on a screening tests:
activated partial thromboplastin time (aPTT), kaolin clotting time (KCT), dilute Russell’s
viper venom time (dRVVT), dilute prothrombin time (dPT), Textarin time.
2. Failure to correct the prolonged coagulation time on the screening test by mixing
with normal platelet-poor plasma.
3. Shortening or correction of the prolonged coagulation time on the screening test
by addition of excess PL.
4. Exclusion of other coagulopathies, e.g., factor VIII inhibitor or heparin, as
appropriate.
The sites of action of the different assays are presented on Figure 3.
Immunologic assays for ACA
ACA react with CL and other anionic PL in solid-phase immunoassays. ACA are
commonly detected by ELISA. Microplate wells are coated with CL, blocked with a
solution of animal serum diluted in buffer, and then incubated with dilute patient serum.
The bound antibodies onto the coated wells are then detected using enzyme-conjugated,
isotype-specific secondary antibody and a chromogenic substrate (Loizou et al, 1985).
- Isotypes
Reference sera that are isotype specific (IgG, IgM, and IgA) are now available. IgG and
IgM ACA concentrations are expressed in units. By definition, one unit represents
cardiolipin binding activity of 1 µg per ml of affinity-purified ACA antibody from
reference sera. IgM is measured in MPL units (1 MPL unit = 1 µg of affinity-purified IgM
ACA from an original reference serum) and GPL units are used for IgG (1 GPL unit = 1 µg
of affinity-purified IgG ACA from an original index serum sample).
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- Titer
Reporting the test results, it is important to identify the titer together with the isotype. The
titer of ACA can be presented as high, moderate, low, or negative. In many cases of
moderate or low titer, ACA are transient antibodies as a result of intercurrent infections.
Therefore, it is important that the initial positive result is repeated after 6-8 weeks.
Persistence of ACA is one of the criteria necessary to establish the diagnosis of APS. The
identification of a positive test result depends upon the laboratory’s care in identifying an
appropriate normal reference interval. The distribution of the normal range is logarithmic
rather than Gaussian. In order to quantify ACA, four house standards from two University
Hospital laboratories were compared with the standards provided by the Antiphospholipid
Standardization Laboratory by using two different plates and two different buffered protein
solutions. Slopes from the serial dilutions of each of the four house standards were found
comparable. In contrast different slopes were obtained when using the ASL standards
which consist of a mixture of sera. These results indicated that dilutions of single sera are
more suitable than mixture of sera when quantification of ACA is required (Rupin et al,
1994). The team from Haemostasis Unit at University Hospital of Geneva studied the
positivity variation for ACA in 61 patients and 42 controls by comparing two commercial
kits (A and B) with their own assay (C). The results were as follows: 50.8% ACA
positivity for A, 57.4% for B and 50.8% for C. As for controls the concordance in patients
was better between kit A and assay C than between kit B and assay C (de Moerloose et al,
1990). The performances of nine commercial kits and an in-house method for the
quantitation of ACA have been evaluated in a multicenter study (Reber et al, 1995).
Marked differences in positivity rate between kits were observed, ranging from 31 to 60%
for IgG and 6 to 50% for IgM. This study showed that differences in positivity rates
between the commercial kits might contribute to the differences in ACA prevalence rate
found in the literature. The choice of cut-off levels might partly explain the moderate
concordance between the kits. Sustained efforts on anticardiolipin standardization have
resulted in improved agreement between commercial assays.
The ACA ELISA is a sensitive test, but its disadvantage is that it may be positive in a
number of disorders other than APS. Alternatively, newer assays that use β 2GPI or a
mixture of negatively charged PL (APL ELISA Kit) have been proposed for more specific
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measurements of antibodies present in APS (Roubey et al, 1995). The epitope recognized
most often by ACA is thought to be β 2GPI. Thus, ELISA kits are using β 2GPI to
distinguish autoimmune ACA from true ACA that do not require β 2GPI for direct binding
to CL. Comparisons for the sensitivities and specificities of the standard ACA ELISA,
anti-β 2GPI ELISA, and APL ELISA Kit were made (Pierangeli et al, 2001). They showed
consequently 100%, 74%, and 98% sensitivity of the three assays for APS. Their
specificity was, as follows: 60%, 82% and 99%. Inter-laboratory variability of anti-β 2GPI
measurements (IgG and IgM) was investigated in the frame of the European Forum on
Antiphospholipid Antibodies and its Standardization Group (Reber et al, 2002). They
found that the rate of positivity varied from 50% to 93% for IgG and from 13% to 70% for
IgM anti-β 2GPI. Excellent concordance between centers occurred only in 13% of cases for
IgG and in 6% of cases for IgM, because many selected samples were low-positive.
Despite the large variability of anti-β 2GPI measurements between centers, the authors
found a good agreement with high- and medium-positive samples. According to an
agreement reached during the eighth International Symposium on Antiphospholipid
Antibodies (Wilson et al, 1999), the LA test and ACA ELISA should be used primarily in
the diagnosis of APS. Moderate-to-high positive ACA or LA test results and well-
documented clinical features are enough for diagnosis of APS to be made. If these test
results are negative or equivocal, more specific tests, such as anti-β 2GPI ELISA or anti-PL
ELISA Kit might be used to confirm the diagnosis of APS.
Coagulation assays for LA
LA are defined as immunoglobulins that inhibit PL-dependent coagulation tests in the
absence of specific coagulation factor inhibition. Generally, LA are suspected when one of
several screening assays, most commonly aPTT, is prolonged. A suspected LA is further
evaluated using an inhibitor screen (mixing study), in which the aPTT of a mixture of the
test and normal plasma is measured. LA usually prolong the clotting time of normal
plasma immediately, but on occasion prolongation requires incubation (Clyne et al, 1988).
If the initial mixing study shows correction of the abnormal clotting time, then an assay for
time-dependent inhibition should be performed. A diagnosis of LA should not be made on
the basis of multiple abnormal screening assays and mixing studies only. If the mixing
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studies indicate the presence of circulating inhibitor, then LA confirmatory studies should
be performed. Factor assays may be used when mixing studies show correction, suggesting
a factor deficiency, when the LA confirmatory studies are negative or when a specific
factor inhibitor is suspected (Brandt et al, 1995).
- Screening assays for LA (Table 2)
TABLE 2. Main screening assays for LA
Test Coagulation pathway
aPTT (activated Partial Thromboplastin
Time)
daPTT
KCT (Kaolin Clotting Time)
dRVVT (dilute Russell's Viper Venom Time)
dPT (dilute Prothrombin Time)
Textarin time
contact activation of the intrinsic pathway
contact activation of the intrinsic pathway
contact activation of the intrinsic pathway
final common pathway (RVV directly
activates FX to FXa and to a lesser extent
FIX to FIXa
VIIa TF activation of FIX, FIXa activation
of FX, VIIa TF activation of FX and the
prothrombinase reaction
Pt activator (in the presence of FV, calcium
and PL)
The presence of LA is often first suspected when the aPTT is abnormal and fails to correct
with normal plasma. Among screening coagulation tests, the aPTT is more sensitive than
PT, probably because of the lower PL content of the reagent used in aPTT. A common
concept is that the amount of PL in the test system is a critical determinant of sensitivity.
Test systems with reduced amount of PL such as daPTT, KCT, dRVVT, dPT thus might
offer the possibility of increased sensitivity due to their low PL concentration (Working
Group on Haemostasis of the “Société Française De Biologie Clinique”, 1993). The
Textarin time was found to be the most sensitive screening test for LA when compared
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with the other test systems. Data show that the PL concentration is not the only
determinant of assay sensitivity to LA. Altering the incubation time of aPTT, rather than
the PL concentration, was a sensitive way of detecting LA (Robert et al, 1994) but it does
function with few cephaloplastins. Furthermore, for partly unknown reasons, some assays
appear to be more sensitive to certain subgroups of LA. Therefore, at least two different
types screening assays must be performed before the presence of LA can be ruled out. The
presence of platelets or platelet fragments in plasma after centrifugation can affect the
results of coagulation tests, particularly when plasmas are frozen before testing, and the
use of twice centrifuged plasma, or filtration through a 0.2-µm filter, has been advocated to
avoid this problem (Ames et al, 1996). This is particularly important for assays without
added PL (KCT) or with very low amount of PL (dPT). The residual amount should not
exceed 10 G/l (Exner et al, 2000).
The protein dependence of LA may affect the tests differently. For example, it has been
shown that KCT is most abnormal in the presence of Pt-dependent antibodies (Galli et al,
1995), whereas the dRVVT is mainly abnormal in the presence of β 2GPI-dependent
antibodies.
- Mixing studies for LA
The presence of an inhibitor is usually documented by mixing patient plasma with normal
plasma and by demonstrating a persistence of an abnormal clotting time. The sensitivity of
LA testing depends on the ratio of patient plasma to normal plasma used to detect the
anticoagulant effect, and these variations have not been standardized. The most common
ratio of patient to normal plasma, used in mixing studies, is 1:1. However, Clyne et al
(1993) showed a relatively high incidence of negative mixing studies using a 1:1 ratio in
aPTT system. Some authors have suggested 4:1 mixture for evaluation of mildly prolonged
aPTT (McNeil et al, 1991). Other groups have proposed a 1:4 mixture for some cases
(Petri et al, 1997).
The problem with negative mixing studies may be related to the observation that some LA
show time-dependent inhibition in clotting assays. Up to 15% of LA may show correction
of the prolonged clotting time if tested immediately after mixing but a lack of correction if
the clotting time is repeated after incubation of patient and normal plasma. These data have
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been challenged by Exner (2000), who demonstrated that upon buffering the mixture, the
time dependence is abolished.
There is a lack of uniform criteria for the evaluation of mixing studies. One approach is to
determine an index of correction. The basic formula for this index is:
Index= 100x(b-c)/a, where a= clotting time of patient plasma, b= clotting time of patient +
normal plasma mixture, and c= clotting time of normal plasma.
- Confirmatory assays for LA
A number of confirmatory assays based on the principle of adding to or altering the PL
content of the test system have now been described (Table 3). They can be grouped
according to the screening assay on which they are based. In the diagnosis of LA, it is
important to use a confirmatory study that corresponds to the screening test which is
abnormal.
TABLE 3. Confirmatory assays for LA
Screening assay Source of PL
aPTT based assays
dRVVT
KCT
dPT
Platelet neutralisation procedure, PL
dilutions, hexagonal phase PL
Platelet vesicles, platelets
Platelet vesicles, liposomes
PL dilutions
The basis of these assays is to determine the effect of altering the PL content of the assay
system, by adding platelets, platelet vesicles or hexagonal phase PL. The majority of test
systems that are now employed to demonstrate PL dependence use increased
concentrations of PL or frozen thawed platelets. The increased PL or platelet membranes
"neutralize" or "bypass" LA. The platelet neutralisation procedure uses washed frozen and
thawed platelets as a source of PL and is most commonly used in aPTT (Triplett et al,
1983). The hexagonal phase PL test is based on the finding that PE is capable of
supporting coagulation test and can effectively neutralize LA activity. Comparing these 2
tests, platelet neutralisation procedure and hexagonal phase PL in systemic lupus
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erythematosus plasmas, Reber et al (1994) found that platelet neutralisation procedure
gave a higher rate of detection than hexagonal phase PL and other tests of detection.
Addition of platelets may also shorten the aPTT in the presence of anti-F VIII antibodies.
As shown in Figure 4, LA and ACA may occur independently or may coexist. LA and
ACA activities may be due to the same antibody, or the activities may be physically
separable (Champley, 1991). There is another family of antibodies, called reagin
antibodies, which are observed in patients with APS. This group of antibodies reacts with
the Venereal Disease Research Laboratory (VDRL) reagent. The VDRL reagent denotes a
mixture of antigens, including CL, cholesterol and lecithin (Singh et al, 2001).
Indications for laboratory testing
Because of the high risk of thrombosis and miscarriage and the influence of positive APLA
tests on therapy, screening can be justified in a many subjects. In relation to venous
thromboembolism, all subjects with apparently spontaneous events should be considered
for testing. The prevalence of positive tests is likely to be lower in thrombosis secondary to
identified events such as surgery or trauma. Recurrent venous thromboembolism, even in
the presence of other risk factors, may be an indication for testing for APLA. Subjects with
stroke and those with peripheral arterial occlusive events occurring at a young age (for
example less than 50 years) should be tested for APLA, especially when risk factors for
atheromatous arterial disease are not prominent. The case can be made also for screening
older subjects who are non-smokers and are not exhibiting other risk factors such as
hypertension, diabetes mellitus or dyslipidaemia. Where recurrent arterial occlusive events
occur despite antithrombotic prophylaxis, APS should be excluded. In subjects with SLE,
APLA should be sought as part of the assessment of the autoantibody profile.
Because miscarriage is a common phenomenon, screening for APLA is not informative
after a single event. In women with three or more consecutive pregnancy losses, testing for
APLA should be part of the comprehensive investigation, including gynaecological,
hormonal and chromosomal assessments. Unexplained loss of any morphologically normal
fetus in the second or third trimester may be an indication for testing for APLA.
Consideration should also be given to the possible diagnosis of APS in women with early
severe pre-eclampsia or severe placental insufficiency in any pregnancy. Because maternal
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antiphospholipid antibodies may be downregulated during pregnancy, tests are best
performed preconceptually or early in pregnancy when possible (Godeau et al, 1997).
IV. CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME
Clinical relevance of APLA
Although APLA were first described more than four decades ago, the mechanisms
underlying their association with clinical events have not been completely defined.
APLA in healthy population
Estimates of the prevalence of APLA in healthy populations vary depending on the criteria
used. It has been reported that ACA exist in approximately 5% of normal individuals,
although less than 2% showed persistently elevated levels (Vila et al, 1994).
APLA in patients with no thrombosis or pregnancy morbidity, but with infections, drugs,
auto-immune disorders
APLA are commonly found after certain acute or chronic infections. They develop in as
many as 30% of children after viral infections. A high proportion of children and adults
infected with mycobacteria, malaria, Q fever, hepatitis C, parvovirus B19,
cytomegalovirus, etc. develop APLA (McNeil et al, 1991; Mengarelli et al, 2000). In HIV-
positive patients, Constans et al (1998) found a 41% frequency of IgG APLA; IgM APLA
were positive in 7% and IgG anti-β 2GPI were rare (3-4%). In Geneva University Hospital,
ACA were determined by an ELISA assay in 116 HIV-1-infected patients and positive test
was found in 23.3% of the patients with a predominance of IgG ACA isotype (Bernard et
al, 1990). Another study at Geneva University Hospital included 43 HIV-positive and 29
HIV-negative heavily transfused haemophiliacs. The presence of ACA was detected in 10
patients, all of them infected by HIV (Naimi et al, 1990).
The increase of APLA in patients infected with HIV may be due to disruption of the cell
membranes which leads to the exposure of normally “hidden” PL during apoptosis
(Clements et al, 1995). APLA from HIV-infected individuals tend to recognize various PL,
most commonly PS (Petrovas et al, 1999). In addition, ACA in patients infected with HIV
recognize oxidized CL more strongly than reduced CL. This finding, in conjunction with
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the increased oxidative stress found in these patients, may further explain the generation of
APLA as a result of neoepitope formation by oxidized PL (Tzavara et al, 1997).
Some medications associated with the development of APLA include neuroleptics,
quinidine and procainamide (Merrill et al, 1997). APLA could be induced also by
phenothiazines, chlorthiazide, ethosuximide, oral contraceptives or alpha-interferon
(Kutteh et al, 1997). The duration of APLA after infection or discontinuation of drug
exposure is not well established, and the risk of thrombosis is variable.
LA have been identified in 10% to 20% of patients with well-established SLE, and ACA-
in 30% to 50% of the individuals with SLE (Sammaritano et al, 1990) who present the
majority of cases of secondary APS.
APLA also occur in patients with other autoimmune disorders like Sjögren’s syndrome,
mixed connective tissue disease, rheumatoid arthritis, systemic sclerosis, ankylosing
spondylitis, vasculitis, idiopathic thrombocytopenic purpura, etc. APLA are found also in
patients with diabetes mellitus, Crohn's disease and autoimmune thyroid disease. APLA
can be detected in some patients with malignancies such as thymoma; carcinoma of the
lung, kidney, ovary, cervix uteri, prostate; lymphoma, leukemia and various
myeloproliferative disorders (Kutteh et al, 1997).
APLA in patients with thrombosis and/or pregnancy morbidity / primary APS /
According to the Sappporo’s criteria for APS, all individuals with APS have by definition
ACA and/or LA. Recent data show that LA are the strongest risk factor for
thromboembolic events in patients with primary APS and secondary APS (Galli et al,
2000). No clear results have been reported showing that the measurement of ACA defines
the patient’s thrombotic risk. It has been found that ACA do not recognize anionic PL but
are directed against plasma proteins bound to suitable anionic (PL and other) surfaces.
Among them, β 2GPI and Pt are the most common antigen targets. β 2GPI is required by the
great majority of ACA to react with CL in immunoassays (Galli et al, 1990). A recent
study examined the distribution of APLAs among patients with SLE. The most prevalent
APLA were found to be anti-β 2GPI antibodies. They were observed in 36.8% of all
patients with SLE, being present in 40.4% of SLE patients with secondary APS and 34.9%
in SLE patients without clinical features of APS (Bruce et al, 2000).
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Clinical criteria for APS
Preliminary criteria for APS were formulated during the International workshop in
Sapporo, 1998. Definite APS is considered to be present in a given patient when at least
one of the following clinical criteria exist:
A) Vascular thrombosis
One or more clinical episodes of arterial, venous, or small vessel thrombosis, in any tissue
or organ. Thrombosis must be confirmed by imaging or doppler studies or histopathology,
with the exception of superficial venous thrombosis. For histopathologic confirmation,
thrombosis should be present without significant evidence of inflammation in the vessel
wall.
B) Pregnancy morbidity
1. One or more unexplained deaths of a morphologically normal fetus at or beyond
the 10th week of gestation, with normal foetal morphology documented by ultrasound or by
direct examination of the fetus, or
2. One or more premature births of a morphologically normal neonate at or before
the 34th week of gestation because of severe preeclampsia or eclampsia, or severe placental
insufficiency, or
3. Three or more unexplained consecutive spontaneous abortions before the 10th
week of gestation, with maternal anatomic or hormonal abnormalities and paternal and
maternal chromosomal causes excluded.
Vascular thrombosis
A retrospective analysis of 100 patients with primary APS and secondary APS (Munoz-
Rodriguez et al, 1999) reported one or more thrombotic episodes in 53% of the patients:
40% had venous thrombosis, 53% had arterial thrombosis, and 7% had combined arterial
and vein thrombosis (Table 4).
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TABLE 4. Clinical manifestations of vascular thrombosis
Venous thrombosis deep venous thrombosis
superficial thrombophlebitis
pulmonary embolism
unusual sites- hepatic, mesenteric, axillary, pulmonary,
renal veins
Arterial thrombosis coronary, carotid, aorta and peripheral artery thrombosis
cerebrovascular thrombosis
retinal vessel thrombosis
Thrombotic complications cardiovascular manifestations
central nervous system manifestations osteoarticular and
cutaneous manifestations
Venous thrombosis
Venous thrombosis most commonly involve the deep venous system of the lower limbs
and the pelvic region. Cervera et al (2002), studying 1000 patients with primary APS and
secondary APS, showed that deep vein thrombosis is the most common clinical
complication (38.9%). Deep vein thrombosis occurs most often in high-risk settings, such
as pregnancy, prolonged immobilisation, or use of oral contraceptives. A pulmonary
embolism was observed in 14%, and superficial thrombophlebitis in the leg in 11.7% of
the patients during the evolution of their disease. Thrombi at unusual sites such as the
hepatic, mesenteric, axillary, pulmonary, and renal veins, cerebral venous sinus, and
inferior vena cava have also been reported.
Less than 1% of episodes of venous thromboembolism are fatal. Although significant
morbidity from post-thrombophlebitic syndrome develops in around 30% of individuals
with lower limb deep vein thrombosis, a significant proportion of these eventually
becomes asymptomatic (Prandoni et al, 1999).
- Recurrence of thrombosis
Munoz-Rodriguez et al (1999) observed that in most of the patients with recurrent episodes
of venous thrombosis, the thrombotic event was at the same site as the previous
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thrombosis. In recurrent venous thrombotic events in the legs, 45% of the individuals had
recurrence in the same leg, 20.7 % in the controlateral and 30.5% in both legs
(Margaglione et al, 1999). A prospective four years follow-up study compared the risk of
recurrent venous thromboembolism in 412 patients with a first episode of venous
thromboembolism, with or without APLA (Schulman et al, 1998). The risk of recurrence
was found to be 29% in patients with ACA versus 14% in those without antibodies. The
rates of recurrence were 10% per year in patients with ACA and 4% per year in those
without such antibodies. The presence of elevated titers of ACA 6 months after an episode
of venous thromboembolism was proposed as a predictor for an increased risk of
recurrence of thrombosis and death. Recurrences of thrombosis were observed in 19% of
the episodes treated with long-term oral anticoagulation with warfarin sodium or
dicoumarol, in 42% treated prophylactically with aspirin, and in 91% in which
anticoagulant/antiaggregant treatments were discontinued, which indicates the benefit from
prolonged oral anticoagulation. Nojima et al (2001) found the presence of anti-protein S
antibodies as a significant risk factor for venous thrombosis but not for arterial thrombosis.
Arterial thrombosis
Arterial thrombi can occur in any central or peripheral vessel. The most common arterial
locations are the aorta, iliofemoral, cerebral, coronary and retinal arteries. The cerebral
arterioles are the most common site of arterial thrombosis in APS. Peripheral arterial
occlusion, with gangrene, is less common. In the study of Cervera et al (2002), 19.8% of
the patients with APS had a stroke, and 11% had transient ischemic attack. Myocardial
infarction was observed in 5.5% of the cases; arterial thrombosis of the legs has been
found in 4.3%; from the ophtalmologic manifestations 5.4% of patients had amaurosis
fugax and 1.5% had retinal artery thrombosis. Arterial thrombosis carries a much higher
risk of morbidity and mortality due mainly to cerebral ischemia. More prolonged and
intensive anticoagulant therapy is recommended.
- Recurrence of thrombosis
Krnic-Barrie et al (1997) observed recurrent arterial thrombosis in 55% of patients with a
primary and in 38% of the individuals with a secondary APS. The recurrent arterial events
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were found mainly in the white race. Schulman et al (1998) reported 28% risk of
recurrences of thrombosis in patients with a low positive titer of ACA (5 to 35 GPL units),
and 38% risk of recurrences in patients with moderate or high titer (>35 GPL units). In
Geneva Vogel et al (1991) investigated a group of 65 patients with SLE and found that half
of patients had ACA associated with arterial thromboembolic events. Nojima et al (1997)
studied the relationship between arterial or venous thrombosis and the levels of ACA
and/or existence of LA. They observed that the prevalence of thrombosis was higher in a
ACA and LA positive patients (84%) than in ACA only positive patients (16%), or LA
only positive patients (9%). Furthermore, in these patients positive for the two tests, all
patients with a high positive level of ACA had arterial thrombosis indicating that a high
ACA activity combined with a LA positive result might be a risk factor for arterial
thrombosis. In a recent study the authors reported that both anti-β 2GPI and anti-Pt
antibodies might be also significant risk factors for arterial thrombosis but not for venous
thrombosis (Nojima et al, 2001).
Thrombotic complications associated with APLA
- Cardiovascular manifestations
The most common cardiac lesions described in APS patients are heart valve lesions
including thickening, stenosis, vegetation formation and mitral regurgitation. Valvular
abnormalities were found in 36% of patients with primary APS and in 48% of patients with
secondary APS (Nesher et al, 1997). Deposition of APLA in the subendothelial layer is
suggested as the pathogenic mechanism (Durrani et al, 2002). Angina pectoris was found
in 2.7% of the cases, myocardiopathy in 2.9% and subclavian vein thrombosis in 1.8%
(Cervera et al, 2002).
- Central nervous system manifestations
The cerebral vasculature is a common site of arterial thrombosis in APS (Sheng et al,
1998). Multiple subcortical white-matter infarcts secondary to cerebral ischemia the most
frequent finding on magnetic resonance imaging. Levine et al (1995), in their prospective
study of 81 consecutive APS patients who developed cerebral ischemia, reported a
recurrence rate of 31% during a follow-up period of 3 years. The median time to
32
recurrence was 7.9 months; an IgG APL titer greater than 100 GPL was associated with an
even shorter recurrence time. The reported frequency of neurological complications in
APS patients was as follows: stroke in 42%, migraine headaches in 13-20%, epilepsy in 3-
7%, multi-infarct dementia in 2%, chorea in 1%, and cerebral vein thrombosis in 0.7%
(Munoz-Rodriguez et al, 1999; Cervera et al, 2002). Cerebral venous thrombosis was more
common at a younger age and had a more extensive involvement in patients with APS
(Carhuapoma et al, 1997). Seizures, transverse myelitis and chorea associated with APS
were likely to be due to an interaction between central nervous system cellular elements
and APL rather than thrombosis, although a firm link has not been established between
these features and APS (Brey et al, 1998).
- Osteoarticular and cutaneous manifestations
As reported by Cervera et al (2002), the most common skin manifestations of APS are
livedo reticularis (24.1%), leg ulcers (5.5%), pseudovasculitic lesions (3.9%) and digital
gangrene (3.3%). They have been most commonly found on the extremities due to
superficial venous thrombosis and thrombo-phlebitis. Avascular necrosis of bone was
found in 2.4%, and arthritis in 27% of the patients with APS (Cervera et al, 2002).
Pregnancy morbidity
Pregnancy loss is a defining criterion for APS and occurs with a particularly high
frequency in SLE patients. In addition to embryonic losses (before 10 weeks gestation) or
foetal losses (after 10 weeks), APS is associated with a number of potential serious
obstetric complications, including thrombosis, severe preeclampsia, utero-placental
insufficiency, foetal distress and iatrogenic preterm birth (Table 5). These complications
have significant maternal consequences, and they also may contribute to foetal loss. They
may be associated also with other thrombophilic disorders such as factor V Leiden or
G20210A mutations.
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TABLE 5. Obstetrical complications in APS
Recurrent pregnancy losses
Unexplained second or third trimester loss
Foetal death
Intrauterine growth retardation
Premature birth
Severe preeclampsia
Utero-placental insufficiency
Pregnancy-related thrombosis (venous or arterial)
Cervera et al (2002) analysed 590 women with APS who had 1 or more pregnancies: 74%
of them succeeded in having 1 or more live births. The most common obstetrical
complications in the mothers were preeclampsia (9.5% of pregnant women), eclampsia
(4.4%) and abruptio placentae (2%). The most common foetal complications were
embryonic loss in 34.5% of the pregnancies, foetal loss in 16.9% of the pregnancies, and
premature birth in 10.6% of life births.
In women with SLE, a previous adverse outcome was identified as the most important risk
factor for another miscarriage in a subsequent pregnancy (Finazzi et al, 1996). Faden et al
(1997) observed that the presence of anti-β 2GPI antibodies correlates well with some
obstetrical complications, mainly eclampsia and preeclampsia. Anti-IgM anti-β 2GPI
antibodies correlated well with a history of pregnancy loss (Forastiero et al, 1998).
In 1996, Oshiro et al performed a retrospective study of 366 women with two or more
consecutive pregnancy losses, where 79 of them were noted to have LA or ACA, and 290
did not. Both groups had similar rates of pregnancy loss (84%). However, those with APS
had 50% foetal deaths compared with 15% foetal deaths in those without APS.
Approximately 80% of those with APS had at least one foetal death compared with less
than 25% in those without APS. Branch et al (1997) studied 147 women with recurrent
pregnancy loss, negative for LA and with medium-to-high levels of IgG ACA, 104
healthy, fertile controls of similar age and gravidity, and 43 women with well-
characterized APS. Twenty-six (18%) women with recurrent pregnancy loss and nine (9%)
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controls tested positive (above the 99th percentile) for APLA. Sera from five (3.4%)
women with recurrent pregnancy loss and four (3.8%) controls demonstrated binding to PL
antigens other than CL.
Other manifestation of APS
Thrombocytopenia
Thrombocytopenia was observed in 30-52% of patients with APS (Munoz-Rodriguez et al,
1999; Cervera et al, 2002). It was found in 21% of the cases with primary APS and in 38%
of cases with secondary APS. Thrombocytopenia in secondary APS patients was
significantly associated with the presence of ACA at medium-high titer (Amoroso et al,
2003). It was usually mild (platelet count above 90 G/l) and, except in very severe cases,
no bleeding was observed. Similarly to immune thrombocytopenias, pathogenic antibodies
were directed towards epitopes on platelet membrane glycoproteins and were distinct from
"antiphospholipid" antibodies (Godeau et al, 1997). Galli et al (1994) measured in 68
patients with APLA also anti-GPIb/IX and GPIIb/IIIa IgG, directed against platelet
membrane-associated glycoproteins. Increased plasma levels of these anti-glycoprotein
antibodies were found in 40% of cases. Furthermore, APLA have been reported in around
30% of subjects with typical immune thrombocytopenias.
Atherosclerosis
Recent studies demonstrated that EC activation induced by APLA might accelerate
atherosclerosis associated with APS (Ross et al, 1999). Several studies have shown a close
link between an atherosclerotic process and APS (Harats et al, 1999; Bruce et al, 2000 (b)).
Catastrophic APS
Catastrophic APS is a rare, accelerated form of APS. The patients with catastrophic APS
present with wide spread noninflammatory thrombi involving the kidneys, lungs, heart,
gastrointestinal tract, liver, the central nervous system as well as adrenal glands, in various
combinations. Individuals presented with a clinical picture of acute multi-organ thrombosis
with a 60% mortality due to myocardial infarction, acute respiratory distress syndrome,
renal failure, or stroke (Asherson et al, 1996; Triplett et al, 2000). In the study of Asherson
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et al (2001), a total of 80 patients with catastrophic APS were analyzed. The most
important manifestations found at the onset of the episode were cardiopulmonary (25%),
neurologic (22%), abdominal (22%), and renal (14%) with a very high mortality (48%).
V. PATHOGENESIS OF THE ANTIPHOSPOLIPID SYNDROME
The pathogenesis of APS is not completely clear. One hypothesis is that the exposure of
anionic PL during apoptosis may be the driving antigenic stimulus for the development of
APLA (Pittoni et al, 1998). Another hypothesis is that viral or bacterial infections may
initiate the production of APLA. Indeed Gharavi and Pierangeli (1998) observed that
peptides from adenovirus 2, cytomegalovirus or from bacillus subtilis are homologous to
PL-binding region of β2GPI. Some hypotheses to explain the pathogenic mechanisms in
APS rely on the variety of effects of APLA. Indeed PL are involved in the hemostatic
reactions and in biological processes in various manners and APLA have been shown to
affect coagulation at different steps.
APLA have been shown to play a true causal role in development of thrombosis and
obstetrical complications. Indeed immunization of mice with heterologous β2GPI leads to
the development of APLA with recurrent pregnancy loss and thromboembolic
complications (Gharavi et al, 1998). Moreover mice infused with APLA developed
significantly larger thrombi in femoral veins after experimental injury than mice infused
with control antibodies (Pierangeli et al, 1996). Also, a monoclonal human ACA derived
from a patient with APS promoted thrombosis in mice (Olee et al, 1996). Atherosclerosis
in a susceptible mouse model (LDL-receptor knockout mice) was accelerated by
immunization with human ACA from a patient with APS, providing additional evidence
for a causal pathogenic effect (George et al, 1997). The recent characterization of
chimpanzee β 2GPI with the finding of a high prevalence of anti-β 2GPI antibodies in these
animals could propose a possibility of primate models for investigating APS (Sanghera et
al, 2001). It is possible that APLA predispose to thrombosis either by causing cells to
acquire a procoagulant phenotype or by inhibiting cell surface anticoagulant processes.
Additional mechanisms may be involved in the pathogenesis of obstetrical complications.
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Effects of APLA on the cells involved in hemostasis
APLA have been shown to interfere with different types of cells (Table 6) involved in
hemostasis. Other cells such as fibroblasts may also play a role but they are not detailed in
this review.
TABLE 6. Interactions of APLA with cells of the coagulation cascade
Endothelial cells
Platelets
Mononuclear cells
Polymorphonuclear cells
Endothelial cells
Endothelium is a metabolically active interface between the blood and extravascular
tissues. Resting EC exert anticoagulant and antithrombotic properties by preventing
contact of blood with prothrombotic underlying tissues and by producing and presenting
on the EC surface molecules that aid in this function (Pearson et al, 2000). When EC are
activated by different stimulus such as inflammatory cytokines (TNFα, IL-1), bacterial
lipopolysaccharide (endotoxin), viral infections or hypoxia, they express both procoagulant
and proinflammatory properties. It is now known that APLA can bind to and also activate
EC in a similar manner, thus provoking a procoagulant phenotype in EC. In the next
paragraphs we will review the main properties of resting endothelium and the changes after
its activation (Table 7).
- Resting EC
Resting EC are mainly antithrombotic and thus thanks to different mechanisms. The main
molecules are indicated in Table 7 (next page).
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TABLE 7. Participation of EC to the hemostatic properties of the vessel wall
Resting EC Activated EC
Prostacyclin and nitric oxide (+)
Tissue factor pathway inhibitor (+)
Heparan-like sulfate proteoglycans (+)
Thrombomodulin (+)
Endothelial protein C receptor (+)
Protein S (+)
Tissue-type plasminogen activator (+)
Annexin V (+)
Ecto-adenosine diphosphatase and
adenosine triphosphatase receptors (+)
Nitric oxide (-)
Tissue factor (+)
Surface anionic PL (+)
Thrombomodulin (-)
Plasminogen activator inhibitor type I (+)
Surface protease receptors expression (+)
Adhesion molecule receptors expression (+)
(+) increased EC synthesis / expression; (-) decreased EC synthesis / expression
Prostacyclin (PGI2) and nitric oxide (NO), also called endothelium-derived
relaxing factor (EDRF), inhibit synergistically the platelet aggregation and also act as
vasodilators. Besides vasodilatator and antiplatelet properties, nitric oxide has antiadhesive
and antioxidative effects. The best-known antioxidant effect of nitric oxide is the
impairment of lipid oxidation, mainly free fatty acids, phosphatidylcholine and low-density
lipoprotein particles. In view of the proatherogenic effects of oxidized lipids, this
antioxidative activity of nitric oxide is likely to be relevant (O'Donnell et al, 2001). The
mechanism of the antiadhesive action of nitric oxide could also involve antioxidant effects.
Indeed the increased leukocyte adhesion induced by inhibition of nitric oxide synthases
was, at least partially, reversed by intracellular oxygen radical scavengers (Niu et al, 1994).
Both mediators, PGI 2 and NO, are synthesized and released by EC locally and transiently
in response to agonists molecules involved in the coagulation process (e.g. bradykinin and
thrombin) or secreted by aggregating platelets (e.g. adenosine triphosphate and adenosine
diphosphate). PGI 2 and nitric oxide synthesis are each triggered by increases of
intracellular calcium ion concentrations in EC. The elevation of calcium ion, required to
activate fully the production of nitric oxide from its precursor arginine is lower than that
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needed to drive PGI 2  synthesis (Gryglewski et al, 2001). As well as being triggered by
platelet secretory products, PGI 2 synthesis, unlike nitric oxide synthesis, can occur in an
agonist/receptor-independent fashion when platelets aggregate. The activated platelets
secrete PGH 2 or arachidonate that is directly converted to PGI 2 by endothelium.
Tissue factor pathway inhibitor (TFPI) is the physiological inhibitor of TF/factor
VII complex, synthesized by EC and bound to the EC surface (Lupu et al, 1997).
Heparan-like sulfate proteoglycans are localized to the EC surface and they serve
to accelerate the inhibition of thrombin by antithrombin.
Thrombomodulin (TM) is a cell surface proteoglycan produced by EC and
expressed on their surface. TM binds thrombin and decreases its capacity to cleave
fibrinogen but similarly increases its capacity to cleave circulating protein C (Esmon et al,
1995). On thrombin binding, the complex is endocytosed, thrombin is degraded, and TM is
recycled to the cell surface.
Endothelial protein C receptor, expressed by EC, enhances the protein C activation
by the thrombin-TM complex (Laszik et al, 1997; Esmon et al, 2003).
Protein S, synthesized and secreted by EC, is a co-factor that promotes protein C
anticoagulant pathway.
Tissue-type plasminogen activator (t-PA) is a fibrinolytic mediator, secreted from
Weibel-Palade bodies in response to thrombin (Emeis et al, 1997; Huber et al, 2001;
Rosnoblet et al, 1999). Classically, t-PA is activated by binding to fibrin, hence localizing
plasmin generation to the site of a clot. In addition, the EC surface possesses several
binding sites for plasminogen and a specific t-PA receptor, which leads to local plasmin
generation at the EC surface (Hajjar et al, 1995).
Annexin V, expressed on EC, binds with high affinity to the surface PL of both
quiescent and activated EC and inhibits the procoagulant reactions.
Ecto-adenosine diphosphate and adenosine triphosphate receptors are expressed
on EC surface. Adenosine diphosphate receptors induce a response on EC initiating
PGI 2 and nitric oxide synthesis. The major pathway responsible for ending the pro-
aggregatory action of adenosine diphosphate is its sequential dephosphorylation to
adenosine monophosphate and then adenonosine (an inhibitor of platelet aggregation),
which is due to ectonucleotidase enzymes at EC surface (Zimmerman et al, 1998).
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Adenosine diphosphatase, secreted from activated platelets degrades adenosine
diphosphate and thereby limits the effect of platelet released adenosine diphosphate.
- Activated EC
Endothelial activation leads to loss of anticoagulant properties (Table 7) and is
characterised by several modifications.
Diminution of NO
Recent studies in hypercholesterolaemic animals and humans show that the deficiency in
agonist-induced nitric oxide synthesis can be improved by elevating the circulating levels
of arginine. This suggests that the intrinsic levels of nitric oxide synthase are preserved but
that some aspects of the coupling between agonist receptor and nitric oxide synthesis are
disturbed (Maxwell et al, 1998). In contrast with nitric oxide decrease, PGI 2  release is
enhanced in patients with atherosclerosis. This has been attributed as a consequence of
excessive platelet reactivity.
Tissue factor expression
Tissue factor is a transmembrane protein expressed by stimulated EC. It is the
physiological trigger of normal coagulation and a major initiator of clotting in thrombotic
disease (Figure 5). Tissue factor initiates the extrinsic pathway of coagulation by serving
as a cofactor and receptor for factor VIIa to efficiently cleave its substrates, factor IX and
factor X, to their active forms (Roubey et al, 2000).
Increase in cell surface anionic PL
Activated EC have increased exposure of surface anionic PL, which are cofactors for the
coagulation system.
Diminution of TM
Activated EC down-regulate the synthesis and cell surface expression of TM and
consequently reduce the formation of the thrombin-TM complex, thereby limiting
thrombin generation (Laszik et al, 2001).
Secretion of plasminogen activator inhibitor type I (PAI-I)
PAI-I is synthesized and secreted by activated EC. It is the major plasma inhibitor of t-PA,
involved in the regulation of fibrinolysis, degradation of the extracellular matrix and
angiogenesis.
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Release of Von Willebrand factor (vWF)
Activated EC release vWF from storage granules (Weibel-Palade bodies) in response to
thrombin, which participates in platelet adhesion.
Cell surface protease receptors expression
Activated EC serve as a site of protease by expressing cell surface protease receptors. Thus
EC facilitate the formation of enzyme complexes involved in the regulation of coagulation
and fibrinolysis.
Increased adhesion molecule expression
Activated EC express adhesion molecules for leucocytes such as E-selectin, intracellular
adhesion molecule (ICAM-1 and -2), vascular cell adhesion molecule (VCAM-1).
- Effects of APLA on endothelial cells
It has been hypothesized that APLA bind to antigens such as PS, TM and heparan
proteoglycan on EC surfaces (Pierangeli et al, 1999) and that β 2GPI could be a cofactor
facilitating this interaction with EC (Del Papa et al, 1997; Dueymes et al, 1996). Indeed
EC activation by APLA is associated with increased expression of adhesion molecules,
increased synthesis and secretion of proinflammatory cytokines, tissue factor expression,
increased endothelin-1, induction of apoptosis, and EC migration.
Increased expression of adhesion molecules
Activated EC express surface E-selectin, VCAM-1, and ICAM-1 leading to increased
monocytes and leucocytes adhesion. (Simantov et al, 1995; Meroni et al, 2001). Pierangeli
et al (2000) demonstrated that in a pinch-induced thrombosis model APLA enhance
leukocyte adhesion and increase thrombosis. The authors analyzed in vivo leukocyte
adhesion to endothelium in venules of exposed murine cremaster muscle. The
thrombogenic effects of APLA were reduced in transgenic ICAM-1-deficient mice, ICAM-
1/P-selectin-deficient mice and in mice infused with anti-VCAM-1 antibodies.
Increased synthesis and secretion of proinflammatory cytokines
APLA increase EC synthesis and secretion of the proinflammatory cytokines IL-1 and IL-
6. This could further contribute to cell activation in an autocrine manner because specific
antagonists, such as IL-1 receptor antagonist, can inhibit the process (Del Papa et al, 1997;
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Meroni et al, 2000). Thus anti-β 2GPI antibodies can induce an EC activation either
directly or by a cytokine autocrine loop.
Tissue factor expression
 It has been demonstrated that incubation of cultured EC with anti-β 2GPI antibodies result
in an increased production of TF, further supporting the hypothesis that APLA are
procoagulant triggers (Branch et al, 1993 ; Kornberg et al, 2000; Dunoyer-Geindre et al,
2001). Amengual et al (1998) demonstrated by reverse-transcription polymerase chain
reaction that human monoclonal anti-β 2GPI antibodies upregulate tissue factor mRNA on
HUVEC, suggesting that the tissue factor pathway be implicated in the pathogenesis of
APLA related thrombosis.
Increased endothelin-1 (ET-1)
Significantly increased plasma levels of ET-1, the most potent endothelium derived
contracting factor, were found in patients with APS and arterial thombosis (Atsumi et al,
1998). In vitro incubation of EC with human monoclonal anti-β 2GPI antibodies was
shown to upregulate the expression of preproendothelin-1 mRNA.
Induction of apoptosis
A subset of APLA that recognizes annexin V induces apoptosis in EC (Nakamura et al,
1998; Pittoni et al, 1998). In vivo, apoptosis of EC would lead to de-endothelialization and
exposure of the thrombogenic subendothelium (Bombeli et al, 1999). It is hypothesized
that APLA could also displace annexin V that covers the anionic PL on EC membranes,
thus increasing the net quantity of thrombogenic PL exposed their procoagulant phenotype
(Rand et al, 2000).
EC migration
APLA may also interfere with EC migration. This activity could potentially interfere with
re-endothelialization and prolong the exposure of the thrombogenic subendothelium (Lanir
et al, 1998).
Platelets
Platelet binding to activated EC is the next phase in the process of thrombus formation
although the precise mechanisms that mediate EC-platelet interaction are not completely
clear. It was demonstrated that activated platelets are present in patients with APS but
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whether platelet activation in patients with APLA is a direct result of APLA or other
autoantibodies or a consequence of vascular injury is uncertain (Emmi et al, 1997). A
recent study found that APLA in APS have antiplatelet reactivity but there was no
evidence for associated direct platelet-activating ability (Ford et al, 1998). Galli et al
(1996) reported that the evidence that human APLA either bind to or activate platelets is
still uncertain. Lackner et al (2000) also showed that two human monoclonal APLA had no
effect on platelets as determined by flow cytometric analysis of CD62P, CD41, CD42b
expression and fibrinogen binding with and without previous activation with adenosine
diphosphate or thrombin receptor activating peptide (TRAP-6). One possible explanation
for these observations might be the presence of specific antiplatelet autoantibodies that
coexist with APLA in patients with APS (Reverter et al, 2000). However, some
investigators have shown that APLA may induce platelet activation and aggregation in the
presence of low concentrations of agonists such as thrombin, adenosine diphosphate or
collagen (Martinuzzo et al, 1993; Campbell et al, 1995; Nojima et al, 1999). A correlation
was found between the IgG level of ACA and the CD62-positive platelet percentage in
patients with primary APS and, more significantly, in the patients with primary APS and
neurological disorders.
APLA-containing plasma promoted platelet aggregation in a perfusion model (Escolar et
al, 1992). Wiener et al (2001) suggested that the platelet aggregation in APS is induced by
an APLA-complex present in patients’ plasma. The initial trigger in this thrombotic
process is calcium independent, but probably is followed by release, recruitment, and
ultimately fibrin formation by the usual metabolic calcium-dependent fibrinogen binding
pathway. Potential targets for APLA on platelets include platelet-activating factor
(Barquinero et al, 1994), PS (Vazquez-Mellado et al, 1994; Campbell et al, 1995), and
platelet glycoprotein IIIa (Tokita et al, 1996). Recently Ferro et al (1999) characterized 11-
dehydro-TXB2 as a sensitive marker of platelet activation, and found it significantly higher
in patients with SLE and APLA. A statistically significant correlation was found between
plasma levels of vWF and tPA and excretion of this thromboxane metabolite. In a recent
study, levels of platelet activation were investigated in 20 patients with primary APS and
30 SLE patients (14 of whom had secondary APS) by measuring CD63 expression on
platelets and soluble P-selectin levels. Platelet CD63 expression and soluble P-selectin
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levels were significantly higher in patients with primary APS and SLE patients
with/without APS than normal controls (Joseph et al, 2001). Robbins et al (1998)
hypothesized that APLA/β 2GPI complexes could activate platelets to produce
thromboxane A2 (a proaggregatory prostanoid) which could contribute to the
prothrombotic state found in patients with APS. Shechter et al (1999) found that platelet
serotonin concentration in APS patients was significantly lower than that found in the
platelets of normal controls but the reasons of low serotonin levels are still not clear.
Thrombocytopenia is a common finding in patients with APS and a potential association
with platelet activation could exist. It was hypothesized that thrombocytopenia is due to
platelet activation and consumption of platelets on the damaged vascular endothelium
(Walenga et al, 1999). George et al (1999) studied 38 SLE patients and found in 26.3% of
them high levels of β 2GPI containing immune-complexes. There was a positive correlation
between β 2GPI/ immune-complexes levels and the occurrence of thrombocytopenia.
Monocytes
Monocytes are implicated in the pathogenesis of APLA related thrombosis, mainly by
stimulated cell surface expression of tissue factor (Kornberg et al, 1994; Cuadrado et al,
1997). Amengual et al (1998) revealed by flow-cytometry that monocytes from a healthy
donor displayed higher tissue factor antigen expression when incubated in the presence of
APS plasmas than with control plasmas. Stimulation of monocytes from APS patients with
β 2GPI induced substantial monocyte TF, whereas no induction was observed with cells
from patients having APLA without APS. Tissue factor induction on monocytes by β 2GPI
was dose dependent and required circulating type 1 (Th1) CD4+ T lymphocytes and class
II Major Histocompatibility Complex (MHC) molecules (Visvanathan et al, 2000). The
authors previously reported that at least 44% of patients with APS possess Th1 CD4+ T
cells that proliferate and secrete IFN-γ when stimulated with β 2GPI in vitro (Visvanathan
et al, 1999). F(ab)2 fragments of ACA have been reported to induce monocyte tissue factor
expression as well, suggesting the contribution of an Fc-independent component to the
mechanism of antibody-mediated tissue factor activity in APS (Kornberg, 1994). Increased
levels of tissue factor mRNA have been found in the majority of mononuclear cell samples
from patients with APS (Dobado-Berrios et al, 1999).
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Polymorphonuclear cells
Arvieux et al (1995) investigated the ability of six murine monoclonal antibodies to β 2GPI
to induce polymorphonuclear cell functional responses. The six monoclonal antibodies
tested in combination with β 2GPI led to a concentration-dependent activation of human
polymorphonuclear cells. The activation of polymorphonuclear cells was estimated by
their granule release, H2O2 production, and cytosolic Ca2+ increase. The results showed
that the process of polymorphonuclear cell activation depends on monoclonal antibody
binding to these cells through both Fab (via β 2GPI) and Fc domains.
Effects of APLA on coagulation
The effects of APLA on haemostatic reactions are shown on Table 8.
TABLE 8. Procoagulant effects of APLA on the coagulation system
Interference with components of protein C
pathway
Interference with intrinsic pathway of
coagulation
Inhibition of antithrombin activity
Impairment of fibrinolysis
Inhibition of APC pathway
Interference with the activation of protein
C by the TM-thrombin complex
Inhibition of thrombin formation
Binding to cofactors Va and VIIIa
Interference of APLA with the components of the protein C/S pathway
The activation of the coagulation and the protein C pathway are shown in Figures 6, 7 and
8. Once activated by the thrombin-TM complex on the surface of EC, activated protein C
(APC) exerts an inhibitory effect by cleavage of the factor Va and VIIIa; protein S and
factor V are required as cofactors for the APC activity in vivo (Dalhback et al, 1993).
45
Experimental findings (de Groot et al, 1996) consistently showed that APLA may interfere
with protein C axis in multiple ways as described below.
- Inhibition of APC anticoagulant pathway, directly or via its cofactor protein
Several recent studies proposed that APLA cause direct inhibition of the APC pathway and
investigated the correlation of APLA specificity and APC pathway inhibition. Bokarewa et
al (1994) studied the effect of 38 IgG fractions with either ACA alone or both ACA and
LA on the response to APC. Five of eight IgG fractions with LA activity showed a
tendency to reduce the effect of APC in the aPTT system and to simulate the activated
protein C resistance (APC-R) phenomenon. No correlation was found between protein C
activity and ACA levels or the extent of clotting time prolongation. In addition, Nojima et
al (2002) found that the co-existence of anti-Pt antibodies and LA activity was a significant
risk factor in the pathogenesis of APC-R in patients with SLE. Mali et al (2001) reported
similar results from 59 unselected children with SLE showing that acquired APC-R was
significantly associated with the presence of LA but not ACA. They proposed that
acquired APC-R could be a marker identifying LA-positive patients at high risk of
thrombosis. Controversially, Martinuzzo et al (1996) found that the acquired APC-R in
patients with APS seems to be associated with ACA and anti-β 2GPI rather than an in vitro
interference by LA. Atsumi et al (1998) demonstrated in vitro that ACA antibodies (not
anti-protein C autoantibodies) can bind protein C via β 2GPI, and suggested that protein C
could be a target of APLA by making a complex of protein C with ACA and β 2GPI,
leading to protein C dysfunction.
In addition, patients with APS were often found to have protein S deficiency. Atsumi et al
(1997) demonstrated monoclonal ACA binding to protein S in presence of a combination
of β 2GPI and CL, with a consequent increase of the affinity of C4b-binding protein for
protein S. Protein S could represent one of the targets for ACA when combined with
β 2GPI and CL, thus explaining the acquired free protein S deficiency and the attendant
risk of thrombosis in patients with ACA. To explore the coagulation/fibrinolytic balance
and its relation with free protein S, Ames et al (1996) carried out a cross-sectional study on
18 thrombotic patients with primary APS and 18 apparently healthy subjects with
persistence of idiopathic APLA. Low free protein S was found in all non-thrombotic and in
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90% of thrombotic patients with defective fibrinolysis. The data are consistent with
increased thrombin generation and accelerated fibrin turnover and fibrinolysis
abnormalities in asymptomatic subjects with APLA. It indicates also a possible central role
for acquired free protein S deficiency in the thrombotic tendency of APS patients.
- Interference with the activation of protein C by the thrombomodulin-thrombin complex
Oosting et al (1993) showed that the anti-TM antibodies inhibiting TM and subsequent
protein C activation are directed against the regions containing the epidermal growth factor
(EGF) domains in SLE patients with a history of thrombotic complications. When TM was
incorporated in PL vesicles, no inhibition by these anti-TM antibodies could be
demonstrated. In addition, anti-TM antibodies could not inhibit protein C activation
mediated by cultured EC. A conclusion was made that anti-TM antibodies inhibit only
soluble TM.
Carson et al (2000) tested 58 patients with LA and found anti-TM antibodies in 30% of the
cases. Similar antibodies were found in only 2% of 201 normal controls. Three IgG
fractions of the 6 purified IgG from patients with anti-TM antibodies inhibited protein C
activation from 40% to 70% compared to no inhibition in 7 healthy controls.
- Inhibition of thrombin formation
Prothrombinase, which consists of factor Xa, factor Va, Ca2+, and PL, converts Pt to
thrombin. Thrombin is the final protease of the coagulation system and, in turn, activates
protein C in the presence of thrombomodulin on endothelial cells. APC completes a
negative feedback loop in the blood coagulation pathway by degrading factor Va and
factor VIIIa and thereby inhibits prothrombinase activity (Stenflo et al, 1884). Using
chromogenic substance assays and human IgM monoclonal ACA, Ieko et al (1999) found
that these monoclonal ACA inhibited both thrombin generation and APC activity.
Thrombin generation without APC was inhibited as well by adding these antibodies. This
inhibition required the presence of β 2GPI and confirmed the data presented previously by
Mori et al (1996).
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- Binding to coagulation-activated cofactors Va and VIIIa in a manner that protects them
from proteolysis by APC
Borrell et al (1992) studied the effect of purified IgM and IgG from 21 patients with APLA
on factor Va degradation by APC on HUVEC. Thirteen of 14 IgM and 8 of 10 IgG from
patients showed an inhibitory effect on factor Va degradation by APC when compared
with control Ig. Oosting et al (1993) investigated the effect of 30 IgG fractions APLA on
APC-mediated factor Va inactivation in the absence and presence of protein S. Three IgG
fractions inhibited APC-mediated factor Va inactivation independent of protein S and four
IgG fractions APLA inhibited in the presence of protein S. The anticoagulant response of
purified APC, added to LA-containing plasmas of 46 patients, was measured through the
amount of factor VIII inactivation and an acquired APC dysfunction was found (Potzsch et
al, 1995). Thirteen of 14 patients with recurrent thrombotic events and 10 of 19 patients
with one single episode of thrombosis showed an abnormal APC response. In contrast,
among 13 patients with LA without symptoms, only one showed an abnormal APC
response.
A subset of APLA reactive with PE was found particularly active in inhibiting the ability
of PE to promote APC-mediated inactivation of factor Va. This effect correlated poorly
with LA activity and it was suggested that this "acquired" APC resistance might be a risk
factor for thrombosis even in the absence of LA (Smirnov et al, 1995).
APLA also interfered with the fibrinolytic pathway through TM inducible fibrinolysis
inhibitor and by increasing PAI-1 activity. These findings suggested that the impairment of
fibrinolytic activity by APLA might be one of the causes of thrombophilic diathesis in
APS (Ieko et al, 1999).
- Interference of APLA with the components of intrinsic pathway
Recent studies reported the presence of antibodies to factor XII in a significant number of
patients with APS suggesting that their presence might lead to acquired factor XII
deficiency (Jones et al, 2000). Jone et al (2002) reported that, although factor XII is a
member of the family of proteins which include plasminogen and Pt, antibodies to factor
XII in patients with APS appear to be distinct from antibodies to Pt. Sugi et al (2001)
reported that certain anti-PE antibodies are not specific for PE, but recognize the contact
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proteins factor XI and prekallikrein independently or in combination with high molecular
weight kininogen. The contact proteins such as high molecular weight kininogen,
prekallikrein and factor XII have anticoagulant and profibrinolytic functions and their
deficiency was found to be associated with recurrent thrombosis. Several studies
confirmed the presence of autoantibodies to the contact proteins in patients with SLE,
thrombosis, and recurrent pregnancy loss.
- Inhibition of antithrombin activity by APLA
The formation of thrombin-antithrombin complexes (TAT) in APS was impaired. Ieko et al
(2000) did not find an increase in level of TAT in APS, while the level of prothrombin
fragment 1+2 increased. Therefore, free thrombin present in patient blood might contribute
to thrombosis in APS.
It was demonstrated that at least some APLA cross-react with highly polyanionic heparin
and heparinoid molecules and inhibit the acceleration of antithrombin activity (Shibata et
al, 1994). Purified IgG from seven patients with APS were reactive with heparin by
ELISA, whereas none of five controls had antiheparin reactivity. Specificity studies
showed that APS IgG antiheparin antibodies were specifically reactive with a disaccharide
present in the heparin pentasaccharide that binds antithrombin. Furthermore, these
antibodies inhibited heparin-accelerated formation of antithrombin-thrombin complexes.
Impairment of fibrinolysis by APLA
Ieko et al (2000) investigated the effect of both β 2GPI and APLA on the activity of
extrinsic fibrinolysis. The authors found that β 2GPI, without PAI-1, did not affect t-PA
activity in a chromogenic assay. When PAI-1 was added to t-PA, the remaining t-PA
activity was increased up to 60% by the addition of β 2GPI. The effect of β 2GPI did not
require PL. Thus, β 2GPI might protect t-PA activity from the inhibition by PAI-1. When
monoclonal ACA were further added to the mixture with a diluted PL, the remaining t-PA
activity decreased to 50 and 80%. Monoclonal ACA appeared to inhibit the effect of
β 2GPI and to elevate PAI-1 activity. Thus, the impairment of fibrinolytic activity by ACA
might be one of reasons for the increased incidence of thrombosis in patients with ACA.
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Additional effects of APLA
As PL bear structural resemblance to low density lipoprotein (LDL), several studies
(Horkko et al, 1997) showed that APLA might show cross reactivity against oxidized LDL.
Oxidized low-density lipoprotein is implicated in atherosclerosis by influencing foam cell
formation and cell cytotoxicity. The production of anti-oxidized low-density lipoprotein
antibodies results in the formation of immune complexes which are taken up at enhanced
rate by macrophages, leading to foam cell formation. George et al (1997) demonstrated in
mice immunized with ACA that developed APS, that infusion with oxidized low-density
lipoproteins aggravated the manifestations of experimental APS. The authors suggested
that cross-reactivity of oxidized low-density lipoproteins with PL might lead to
significantly more severe form of APS.
In summary, although many studies were and are still performed to determine how APLA
might increase thrombus formation in vitro, their mechanism of action remains unclear.
Several studies have proposed that APLA activation of EC, platelets, and monocytes, as
well as their effects on fibrinolysis and proteins C and S, may contribute to the
prothrombotic state in APS. The large variety of proposed mechanisms makes it difficult to
identify either the main primary mechanism. It is possible also that different mechanisms
exist or co-exist among patients and even in one single patient.
Potential mechanisms involved in APLA-associated foetal loss
A relation between APLA and pregnancy loss has been formally recognized for almost 30
years (Nilsson et al, 1975). It is now accepted that APLA can lead to foetal loss and
probably to recurrent preembryonic and embryonic loss. Studies have reported the
presence of thrombi in placenta of patients with APLA-associated foetal loss, as well as
other abnormalities, such as decreases in vasculo-syncytial membranes, villous fibrosis and
hypovascular villi, and an increase in syncytial knots in placenta from 30% to 50% of these
patients (Levy et al, 1998). Donohoe et al (1999) proposed that one of the mechanisms in
APS associated obstetrical complications may involve the binding of APLA directly to the
placenta where they may initiate placental thrombosis and infarction. By
immunofluorescence techniques the authors detected human APLA binding to human
placenta. Heterogeneous binding to normal term placenta, involving the trophoblast
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microvillous surface, the stromal and the peri-vascular regions was demonstrated by
affinity purified APLA from five out of six patients.
However, the frequency and extent of thrombosis might not be sufficient to explain the
high incidence of foetal loss in patients with APLA. Autoantibodies from sera of primary
and secondary APS patients were found to affect reproductive outcome in pregnant mice in
vivo (Matalon et al, 2002). Purified IgG from women with APS and recurrent pregnancy
loss was injected to mice and affected directly the embryo and yolk sac reducing their
growth. The purified IgG ACA reduced yolk sac and embryonic growth more than sera
negative for these antibodies and caused foetal resorptions and growth retardation as well.
In their study, Blank et al (1999) converted the anti-β 2GPI monoclonal antibody into
single-chain and replaced the H and L chains between the pathogenic and non-pathogenic
single-chain anti-β 2GPI. They demonstrated that single-chain of pathogenic anti-β 2GPI
are capable of inducing the same clinical manifestations as the whole antibody molecule in
actively immunized mice. Elevated titers of mice ACA and anti-β 2GPI, associated with
LA activity, thrombocytopenia, prolonged aPTT and a high percentage of foetal
resorptions were detected. Vogt et al (1997) observed that monoclonal anti-PS antibodies
bind to choriocarcinoma cells as well as to trophoblast cells in histologic sections and, like
anti-β 2GPI antibodies, may displace annexin V from trophoblasts. Rand et al (1997, 1998)
found that IgG APLA reduced the levels of syncytiotrophoblast apical membrane-
associated annexin V in placental villi and the release of annexin V into surrounding
media. In addition, trophoblasts and endothelial cells exposed to IgG APLA had
significantly faster coagulation times. The authors proposed that the reduction of this
anticoagulant protein at the maternal-foetal interface might account for the pregnancy loss
in patients with APS.
The effect of APLA on several non coagulation-related placental functions, such as the
secretion of human chorion gonadotropin, was also considered (Gleicher et al, 1992). An
improved reproductive outcome in animal models of APLA-associated foetal loss in
response to nonanticoagulant therapies, such as interleukin-3 or ciprofloxacin, suggested
that mechanisms other than or in addition to thrombosis might contribute to placental
dysfunction during APLA pregnancy (Blank et al, 1998). Holers et al (2002) found that
APLA induce complement activation in the placenta resulting in placental injury, foetal
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loss and growth retardation. They used a murine model of APS in which pregnant mice
were injected with human IgG containing APLA. The authors found that inhibition of the
complement cascade in vivo, using the C3 convertase inhibitor complement receptor 1-
related gene/protein y (Crry)-Ig, blocks foetal loss and growth retardation. Furthermore,
mice deficient in complement C3 were resistant to foetal injury induced by APLA.
In summary, several mechanisms are involved in APS associated pregnancy loss. They
result in uteroplacental insufficiency with usually multiple placental thromboses and
infarcts, provoked by the hypercoagulable properties of APLA.
VI. MANAGEMENT OF THE ANTIPHOSPHOLIPID SYNDROME
Treatment and prevention of venous thromboembolism
The initial management of an acute event, with intravenous monitored unfractionated or
subcutaneous low molecular weight heparin is not really influenced by the diagnosis of
APS. Warfarin therapy should be instituted in the usual way, with a target international
normalized ratio (INR) of 2.5 (range 2.0-3.0). The duration of treatment should be
determined on an individual basis, taking into account the presence of additional risk
factors, the severity of the presenting event and the particular risk of bleeding on warfarin
(Prandoni et al, 1996; Prandoni et al, 1999). Recent studies found that short-term warfarin
therapy was not sufficient for patients with APS due to the high risk of recurrence of
venous thromboembolism. In these cases the use of aspirin did not offer a clear additional
benefit. Schulman et al (1998) demonstrated the beneficial effects of prolonged oral
anticoagulation on patients with ACA after an episode of venous thromboembolism.
Kearon et al (1999), in their study of 162 patients with a first episode of idiopathic venous
thromboembolism, proposed also that these patients should be treated with anticoagulant
agents for longer than usual because of the increased risk of recurrence of thrombosis.
Some other studies (Brunner et al, 2002) reported that patients with APS and recurrent
venous thrombosis should benefit from long term warfarin at higher intensity (INR 3.0-
3.5). Although the risk-benefit ratio of long-term anticoagulation has not yet been clearly
assessed, it is now proposed that for the majority of subjects having persistent APLA, a
lifelong anticoagulant treatment (INR 2.0-3.0) should be provided after the first venous
thromboembolism (Bauer et al, 2003).
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Treatment and prevention of arterial thrombosis
Because of the high risk of recurrence and likelihood of consequent permanent disability or
death, stroke due to cerebral infarction in patients with APS should be treated with long-
term oral anticoagulant therapy, target INR 2.5 (range 2.0-3.0). Extracerebral arterial
thromboembolic manifestations of APS will also warrant consideration of continuation of
long-term anticoagulation with warfarin in many instances. Higher-intensity
anticoagulation had been recommended and may be appropriate in some cases (Guidelines
on oral anticoagulation, 1998), but results of prospective studies are required before the use
of a target INR of 3.0 and more can be unequivocally supported.
The use of aspirin and/or hydroxychloroquine may be protective against thrombosis in
asymptomatic APLA-positive individuals (Erkan et al, 2002). The addition of aspirin 100
mg to antivitamin K (INR 2.0-3.0) is now discussed in case of arterial thrombosis.
Prevention of pregnancy failure
In women with APS and a history of pregnancy complications, there is a particular need
for a close collaboration between specialists. A variety of treatments including
corticosteroids, low-dose aspirin, heparin and immunoglobulins have been used either as
single agents or in combination in an attempt to improve the rate of live births in women
with APLA (Kutteh et al, 1996). Available data are limited by the small number of patients
in each study and by the lack of standardization of laboratory assays used to detect APLA.
The use of corticosteroids in pregnancy is associated with significant maternal and foetal
morbidity and should be avoided (Laskin et al, 1997). In their randomized controlled
clinical trial, Rai et al (1997) reported that treatment with low-dose aspirin and heparin is
applicable to women with a history of recurrent miscarriage associated with persistent
APLA. They recommended treatment with aspirin, 75 mg/d, to be started as soon as the
urine pregnancy test becomes positive. Because the majority of miscarriages occur before
14 weeks of gestation, the authors proposed a low-dose heparin treatment to be
commenced when foetal heart activity is seen on ultrasonography. In the same study (Rai
et al, 1997), unfractionated heparin (5000 IU) was administered twice daily
subcutaneously. At present, although largely used, no low molecular weight heparin
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preparation is licensed for use in pregnancy in Switzerland. However many studies indicate
that low molecular weight heparin preparations are safe alternatives to unfractionated
heparin as an anticoagulant during pregnancy (Sanson et al, 1999). Concerning the
potential risk of heparin-induced osteopenia, discontinuation of heparin therapy at 34
weeks gestation seems reasonable in women with early pregnancy loss and no history of
thrombosis. When late pregnancy complications have occurred previously, continuation of
antithrombotic therapy to delivery is reasonable and postpartum thromboprophylaxis is
indicated in women with a history of thrombosis. Delivery by caesarean section carries an
additional thrombotic risk and it is an indication for perioperative thromboprophylaxis.
Although combination treatment with aspirin and heparin leads to a high live birth rate
among women with recurrent miscarriage and APLA, successful pregnancies may be
complicated by foetal growth retardation, gestational hypertension and premature delivery
(Backos et al, 1999). In summary, optimal management, usually with low-molecular
weight and aspirin, requires close collaboration between the haematologist and the
obstetrician as well as facilities to enable appropriate clinical monitoring and laboratory
testing.
Primary thromboprophylaxis in case of APLA
Controversial data exist regarding the prophylactic treatment of patients positive for APLA
and without history of thrombosis. Incidental detection of low titers of APLA carries a
minimal risk of thrombosis. However, there is convincing evidence to suggest a significant
risk associated with the presence of medium to high levels of APLA. Prophylactic therapy
is not accepted in clinical practice at present, although there is increasing evidence of the
risks of high levels of APLA (Finazzi et al, 1996; Khamashta et al, 1999). Recent
guidelines on the investigation and management of APS by Greaves et al (2000) suggested
the prophylactic use of low-dose aspirin, which was shown to be protective of deep vein
thrombosis in high risk groups (Rai et al, 1997). Prophylactic low-intensity oral
anticoagulation with warfarin and low-dose aspirin has been shown to significantly reduce
the incidence of ischemic heart disease in patients with APS (General Practice Research,
1998). A decision analysis study of patients with SLE, with and without APLA, also
supports the prophylactic use of aspirin (Wahl et al, 2000).
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Thromboprophylaxis with statins in case of APLA
Recent literature reported that statins are the principal and the most effective class of drugs
to reduce serum cholesterol levels. Statins have been also shown to have anti-thrombotic
effects in addition to lower cholesterol and to reduce cardiovascular events, including
myocardial infarction, stroke, and death in patients with or without coronary artery disease
symptoms. The actions of these drugs extend far beyond cholesterol reduction and involve
non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory
responses, smooth muscle cell activation, proliferation and migration, atherosclerotic
plaque stability and thrombus formation. Thus statins may offer an interesting prophylactic
therapeutic approach for APS without the risks associated with anticoagulation. The aim of
this study was to evaluate whether statins could modify the APLA-induced adhesion
molecule expression by endothelial cells.
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PART II: STATINS AND ANTIPHOSPHOLIPID SYNDROME
I. INTRODUCTION
Statins and fibrates are important currently available hypolipemic drug families decreasing
the plasmatic concentrations of atherogenic lipoproteins and thereby lowering the risk of
coronary heart diseases. Fibrates act as an activator of lipoprotein lipase and increase the
catabolism of triglyceride rich lipoproteins. Statins specifically inhibit hepatic cholesterol
synthesis and consequently, by enhancing LDL-cholesterol uptake, decrease circulating
LDL-cholesterol (Figure 11). Statins act as specific competitive inhibitors of HMG-CoA
reductase. HMG-CoA reductase catalyses the 4-electron reduction of HMG-CoA into CoA
and mevalonate, which is a rate-limiting step early in the cholesterol biosynthesis.
II. PHARMACOLOGICAL PROPERTIES OF STATINS
Origin and chemistry
Statins were first introduced into clinical practice in the late 1980s after the chance
discovery of their lipid-lowering effects in 1976 (Endo et al, 1976). The first statins were
produced from fungal metabolites, but now they are synthetically produced. Currently
there are at least six statins in clinical use (Figure 9). Lovastatin was the first statin to be
approved in 1987. Lovastatin, as well pravastatin, are natural products of fungal origin.
The difference between them is that in pravastatin the methyl group is replaced by
hydroxyl group, which differentiate their hydrophilic properties. Simvastatin is a semi-
synthetic derivative: it differs from lovastatin by one extra methyl group added to it.
Fluvastatin is the first entirely synthetic statin, derived from mevalonolactone.
Atorvastatin and cerivastatin present a new generation of highly purified, synthetic statins.
Lovastatin and simvastatin occur in an inactive closed lactone ring form. They are
converted in the liver into the open lactone form. All other statins do not have to be
converted to the active hydroxy acid form in vivo. The statins have structural similarities,
but they have also structural differences that may influence their cholesterol-independent
effects.
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Solubility and protein binding
Statins could be divided in two groups: hydrophilic (pravastatin) and lipophilic
(atorvastatin, simvastatin, fluvastatin, lovastatin, cervistatin). The lipophilic or hydrophilic
nature of statins influences at least in vitro their access to cellular membranes (Figure 10).
It has been shown that hydrophilic statins are distributed much more selectively in hepatic
than lipophilic cells (Ichihara et al, 2002). Because the membrane of extrahepatic cells
consists of lipid bilayers, hydrophilic statins cannot penetrate it, and thus cannot reach the
intracellular enzyme; however the hepatic cell membrane contains organic anion
transporters, which take hydrophilic substances into the cells. Lipophilic statins can enter
extrahepatic and hepatic cells and thus, as shown in Figure 10, inhibit not only the
cholesterol synthesis but also the production of metabolic intermediates in many
extrahepatic tissues. Protein binding of statins varies from 50% (pravastatin) to 98%
(atorvastatin, simvastatin, fluvastatin).
III. STUCTURE AND CHEMICAL INTERACTIONS OF STATINS WITH HMG-
CoA REDUCTASE
Human HMG-CoA reductase consists of a polypeptide chains of 888 amino acids with
three functional portions: residues 1-339 span the membrane of the endoplasmic reticulum
eight times, residues 340-459 connect the membrane portion to C-terminal catalytic
portion and residues 460-888 reside in the cytoplasm. A linker region connects the two
portions of the protein. The three-dimensional structure of the catalytic portion of HMGR
shows a close association of two monomers in a dimer and of two dimers in a tetramer.
Two equivalent active sites are located at the monomer-monomer interface of the dimers
(Istvan et al, 2000). The HMG-binding pocket is characterized by a loop (residues 682-
694). All statins currently in use inhibit HMGR. They are composed of a HMG-like moiety
and of different, largely hydrophobic attachments. Crystal structures of six different statins
bound to the catalytic portion of human HMGR show that their HMG-like moieties bind in
exactly the same way as the HMG moiety of HMG-CoA (Werner et al, 2002). The
hydrophobic compounds of statins occupy the HMG-binding pocket and part of the
binding surface for CoA. Thus, access of the substrate HMG-CoA to the reductase is
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blocked when statins are bound. The tight binding of statins is due to the large number of
van der Waals interactions between inhibitors and HMGR. The structurally diverse, rigid
hydrophobic groups of the different statins are accommodated in a shallow non-polar
groove that is present only when the COOH-terminal residues of statins are disordered.
There are differences in the models of binding among various statins, the new synthetic
statin rosuvastatin having the greatest number of binding interactions with HMGR.
IV. MECHANISM OF ACTIONS AND EFFECTS OF STATINS
Inhibition of cholesterol synthesis
HMG-CoA reductase catalyzes the 4-electron reduction of HMG-CoA into CoA and
mevalonate with oxidation of two molecules NADPH. Statins block this conversion of
HMG-CoA to mevalonate, thus inhibiting an early step of the cholesterol biosynthetic
pathway (Figure 11).
The primary site of action of all statins is the liver. Their extra-hepatic plasma
concentration and permeability, e.g. into vascular cells, differs between statins and depends
mainly on their lipophilicity (Lea et al, 1997; McTaggart et al, 2001). Inhibition of
cholesterol synthesis in hepatocytes upregulates the expression of the hepatic low-density
lipoproteins receptor. As a consequence, low density lipoproteins and its precursors are
cleared from the circulation (Goldstein et al, 1990). In addition, statins may inhibit the
hepatic synthesis of lipoproteins, an important reason for their ability to lower low density
lipoproteins in patients with homozygous familial hypercholesterolemia who have no
functional low density lipoproteins receptors. Furthermore, statin treatment lead to a
modest increase of plasma concentration of anti-atherogenic high-density lipoproteins
(HDL) (Vega et al, 1998) and small reductions (5% to 10%) in triglyceride levels (Bakker
et al, 1996).
The beneficial effects of statins in primary and secondary prevention of vascular disease in
patients with elevated cholesterol levels have been well established (Hebert et al, 1997;
Pedersen et al, 1999; La Rosa et al, 1999; Shepherd et al, 2002; Sposito et al, 2002).
Recently, the efficacy of statins has also been extended to the primary prevention of
vascular disease in subjects with average cholesterol levels (Downs et al, 1998). These
results suggest that statin therapy could reduce the clinical consequences of atherosclerosis
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in a large proportion of the population at risk. Recent studies also suggest that statins have
benefits in reducing ischemic stroke risk by approximately one-third in patients with
evidence of vascular disease (Andrews et al, 1997).
Statins and isoprenylated proteins
By inhibiting L-mevalonic acid synthesis, statins also reduce the synthesis of important
isoprenoid intermediates such as farnesylpyrophosphate (FPP) and
geranylgeranylpyrophosphate (GGPP) (Goldstein et al, 1990), which mediate many of the
cholesterol-independent effects of statins (Figure 12a, 12b). The isoprenoid intermediates
serve as important lipid attachments for the posttranslational modification of proteins.
Numerous proteins undergo prenylation and are thus converted to a more lipophilic state
that allows a protein to interact with cellular membranes. Rho GTPases, including RhoA,
Rac, and Cdc42, are major substrates for post-translational modification by isoprenylation.
A key step in the activation of Rho, which cycles between a GTP-bound and a GDP-bound
state, is the attachment of the isoprenoid geranylgeraniol. The post-translational lipid
modification allows the translocation of inactive Rho from the cytosol to the membrane.
Therefore statins, which block geranylgeranyl synthesis, inhibit Rho membrane
translocation and activity. Experimental evidence suggests that inhibition of Rho
isoprenylation mediates several of the cholesterol-independent effects of statins not only in
vascular wall cells (Amerongen et al, 2000) but also in leucocytes and bones. Each
member of the Rho family serves specific functions in terms of cell shape, motility,
secretion and proliferation, although overlapping functions between the members could be
observed in overexpression systems. Furthermore, Rho family may participate in the
regulation of gene expression of many proteins. Other important prenylated proteins
include the Ras family that requires attachment of a farnesyl group for its actions and plays
a crucial role in cellular differentiation and proliferation, the Rab proteins which are
necessary for vesicle transportation within the cell and the Rap family which is known to
play a role in cell replication, platelet activation and the generation of oxygen radicals
(Laufs et al, 2000).
Many recent studies reported that the effects of statins extend beyond their cholesterol-
lowering capacity (Werner et al, 2002; Takemoto et al, 2001; Case et al, 2002) and most of
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their multiple activities (so called pleiotropic effects) are mediated by the ability to block
the synthesis of isoprenoid products.
Pleiotropic effects of statins on vascular cells
Experimental evidence suggest that statins may influence several events in the vessel wall
that are relevant for the progression of atherosclerosis (Koh et al, 2000)
- Statins and endothelial function
Stimulation of eNOS and inhibition of endothelin-1 (ET-1)
An important characteristic of endothelial dysfunction is the alteration in either the
expression or function of the endothelial vasoactive factors, ET-1 and NO. ET-1 is an
isopeptide synthesized by EC, with powerful vasoconstrictive effects among others.
Atorvastatin and simvastatin inhibited pre-proET-1 mRNA expression and reduced
immunoreactive ET-1 levels (Perera et al, 1998). Seeger et al (2000) demonstrated that
fluvastatin significantly enhanced prostacyclin synthesis and significantly reduced ET-1
production in cell cultures of human umbilical endothelial veins. Since prostacyclin is a
vasodilator and endothelin a vasoconstrictor, fluvastatin might have a significant effect on
hemodynamics by favoring the balance towards vasodilation.
Endothelial nitric oxide has been shown to mediate vascular relaxation and inhibit platelet
aggregation (Radomski et al, 1992), vascular smooth muscle cells (SMC) proliferation and
endothelium-leucocyte interactions (Gauthier et al, 1995). Laufs et al (1998) have shown
that inhibition of HMG-CoA reductase in vascular EC upregulates the expression and
activity of eNOS and prevents their downregulation by ox-LDL. This effect occurs through
an increase in eNOS mRNA stability.
Effects on the EC fibrinolytic activity
Lovastatin and simvastatin have been shown to induce an increase in the local fibrinolytic
activity of EC by stimulating tPA-expression and activity, an effect that was potentiated by
the inhibition of PAI-1 expression (Essig et al, 1998). Wiesbauer et al (2002) showed that
statins decreased mRNA levels for PAI-1 in EC and SMC and increased mRNA levels for
t-PA in SMC.
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Inhibition of TF
Eto et al (2002) demonstrated that simvastatin prevents the induction of tissue factor by
thrombin in human aortic EC and block the increase in tissue factor activity on the cell
surface. Simvastatin also prevented the upregulation of tissue factor expression and
activity in human aortic SMC. Simvastatin prevents tissue factor induction through
inhibition of Rho/Rho-kinase and activation of Akt.
Statins decrease MHC class II antigen expression
Simvastatin selectively decreases interferon-gamma (IFN-gamma)-induced MHC class II
expression (mRNA and protein) in human primary EC through actions on the CIITA
promoter, general regulator of both constitutive and inducible MHC class II expression. In
contrast, simvastatin does not affect the expression of MHC class I, pointing to specific
actions in the MHC class II signaling cascade. In repressing induction of MHC-II and
subsequent T-lymphocyte activation, statins therefore provide a new type of
immunomodulation (Kwak et al, 2001).
Statin effects on angiogenesis
Urbish et al (2002) have shown a double-edged, dose-dependent effects of statins in
angiogenesis signaling by promoting the migration of mature EC and endothelial
progenitor cells at low concentrations of 0.01 to 0.1 µmol/L, and antiangiogenic effects at
high concentrations (> 0.1 µmol/L). Promigratory and proangiogenic effects of atorvastatin
on mature EC were correlated with the activation of the phosphatidylinositol 3-kinase-Akt
pathway. Weis et al (2002) also showed biphasic dose-dependent effects of statins on
angiogenesis that were lipid independent and associated with alterations in endothelial
apoptosis and vascular endothelial growth factor signaling.
- Statin effects on SMC migration, proliferation and apoptosis
Kaneider et al (2001) observed that cervistatin inhibited proliferation of SMC and also led
to an induction of programmed cell death by increasing caspase-3 activity. Muller et al
(1999) demonstrated that lovastatin inhibit SMC proliferation in association with induction
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of apoptosis. Lovastatin induced arrest of cells in G0/G1 phase of the cell cycle and DNA
synthesis was reduced. A significant induction of p21WAF1/Cip1 protein expression was
found by western blot analysis. This led to a strong inhibition of cyclin dependent kinases
resulting in a cell cycle arrest.
- Statin effects on platelet adhesion and aggregation
Platelet activation and aggregation are crucial initial events in the development of
cardiovascular disease and aggravate pathological alterations in the vessel wall. Adenosine
diphosphate release from activated platelets induces further platelet recruitment, followed
by cell aggregation. Adenosine diphosphate causes granule release and thromboxane A2
generation (Daniel et al, 1999). Neutrophils express locomotive activity in response to
adenosine diphosphate and adenosine triphosphate released from activated platelets via
activation of P2Y4 and P2Y6 receptors (Di Virgilio et al, 2001). Direct interactions of
neutrophils and platelets are mediated through P-selectin (CD62P), the expression of
which represents the first step in the formation of a leukocyte-platelet thrombus in vivo
(Konstantopoulos et al, 1998). Statins have been shown to inhibit platelet function. A
potential mechanism might include a reduction in the production of thromboxane A2
(Notarbartolo et al, 1995). Romano et al (2000) reported that statin treatment reduce the
expression of P-selectin on platelets. Thrombin-activated platelets decreased their
adenosine diphosphate and adenosine triphosphate release by coincubation with statins
(Kaneider et al, 2002). Linjen et al (1994) found that pravastatin reduced the membrane
cholesterol content of platelets, suggesting that certain properties of these membranes are
altered in a manner that renders them less prone to participation in thrombosis.
- Statin effects on monocyte/macrophages
Macrophages are important for the development of atherosclerotic plaques. Secretion of
proteolytic enzymes, such as matrix metalloproteases (MMPs), by activated macrophages
may weaken the fibrous cap of the plaque, leading to plaque instability, rupture and
ensuing thrombosis and arterial occlusion (Uzui et al, 2002). Cerivastatin treatment has
been shown to decrease macrophage expression of MMP-1, MMP-3, MMP-9 and TF, as
well to reduce the number of macrophages expressing histone mRNA, a sensitive marker
of cell proliferation (Aikawa et al, 2001).
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Statins decreased the expression of adhesion molecules on monocytes isolated from
patients with hypercholesterolemia (Weber et al, 1997) and also decreased significantly
monocyte chemoattractant protein-1 (MCP-1), which plays a major role in recruiting
monocytes into the vessel wall (Kothe et al, 2000). Lovastatin was found to inhibit
bacterial lipopolysaccharide and cytokine-mediated production of nitric oxide and
expression of iNOS in macrophages probably by inhibiting farnesylation of p21(ras) or
other proteins that regulate the induction of iNOS. Statins also decrease the production of
cytokines TNFα, IL-1, IL-6 by activated monocytes (Pahan et al, 1997; Rosenson et al,
1999; Grip et al, 2000).
Pleiotropic effects of statins on extravascular system
Observational and experimental studies have implicated potential benefit from the
administration of statins for other noncardiovascular diseases, including osteoporosis and
dementia. Statins might have effects on bone formation. Cell culture experiments showed
that murine osteoclast formation can be inhibited by lovastatin (Fisher, 1999).
Furthermore, Sugiyama et al (2000) described that statins increase the expression of bone
morphogenic protein-2, which plays an important role in osteoblast differentiation and
bone formation. Jick et al (2000) presented a case-control study of individuals with
dementia suggesting that those who were prescribed statins had a substantially lowered
risk of developing dementia, independent of the presence or absence of untreated
hyperlipidaemia. Recently, the data of clinical trials revealed also the antineoplastic
potential of statins, particularly with the use of lovastatin in patients with cancer, anaplastic
astrocytoma and glioblastoma multiforme (Larner et al, 1998). Stimulation of apoptosis
could be involved in the beneficial effects of statins for these processes (Muller et al,
1998).
In summary, statins constitute the most powerful class of lipid-lowering drugs. However,
the benefits demonstrated in clinical practice with statin therapy appear to be related, at
least in part, with effects that are independent of their cholesterol-lowering effects.
Extensive research in the last decade suggests that statins have additional beneficial
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effects, related to an improvement in endothelial function, a reduction in blood
thrombogenicity, antiinflammatory properties as well as immunomodulatory actions.
Other effects of statins
Inhibition of dolichol synthesis
The mevalonate pathway also leads to the formation of dolichols, having an essential role
in lipoprotein synthesis, and of ubiquinone, involved in electron transport (Corsini, 1999).
Activation of protein kinase Akt
Phosphorylation of the protein kinase Akt is important in several cellular cascades,
including the endothelial nitric oxide synthase activation and endothelial cell survival. Akt
is activated by several growth factors including VEGF, fibroblast growth factor as well as
shear stress (Edwards et al, 2000). Statins activate the protein kinase Akt via a
phosphoinositol-3-kinase dependent pathway resulting in enhanced eNOS activity,
inhibition of endothelial apoptosis and increased release of endothelial progenitor cells
(Kureishi et al, 2000).
Regulation of caveolin
Caveolae are small plasma membrane invaginations that play an important role in signal
transduction and compartmentalization of signaling molecules. For example, caveolin
forms an inhibitory complex with endothelial nitric oxide synthase (eNOS). Recently,
inhibition of caveolin expression in the presence of statins has been demonstrated,
resulting in an upregulation of nitric oxide release (Feron et al, 2001).
Statins and HMG-CoA independent effects
Until recently, all cholesterol-independent effects of statin treatment were shown to be
mediated by inhibition of mevalonate synthesis. Recently, Weitz-Schmidt et al (2001)
reported that statins bind to a novel allosteric site within the ß2 integrin function antigen-1
(LFA-1), independent of mevalonate production. LFA-1 is important for the adhesion and
co-stimulation of lymphocytes. The authors optimised statins for binding to LFA-1 and
developed selective and orally active LFA-1 inhibitors that suppressed the inflammatory
64
response in murine model of peritonitis. These findings, independent not only of
cholesterol but also of HMG-CoA, open up a new area of research and treatment options.
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PART III: EXPERIMENTAL WORK
As indicated in the previous sections, EC activation by APLA was shown to be a crucial
event in APS. The activated EC express procoagulant and proinflammatory phenotype. EC
activation is associated especially with increased endothelial surface adhesion molecules
expression, thus favoring mononuclear leukocyte adhesion. The aim of my study was to
investigate to what extent statins influence the expression of adhesion molecules by EC
activated by APLA. The working hypothesis was that statins could prevent EC adhesive
properties induced by APLA. A secondary aim was, in case a statin’s effect was observed,
to investigate the mechanism explaining the effect.
The work was started by studying the effect of statins on EC activated by TNF-α. Indeed
TNF-α is well characterized, available in sufficient amounts and previous experiments
have shown a reproducible effect of this cytokine to induce adhesion molecules by EC.
I. PATIENTS AND METHODS
Patients
Sera were collected from 13 patients with clinical symptoms of APS. All patient sera
contained IgG ACA and anti-β 2GPI antibodies at high titer and were LA (+) or LA (-). In
preliminary experiments the ability of purified IgG APLA from these patients to induce a
proadhesive phenotype in HUVEC was tested. APLA from 8 patients were found to be
able to activate HUVEC increasing surface adhesion molecules and these 8 APLA were
used in this study.
Reagents
TNF-α was from R&D Systems (Mineapolis, MN, USA). Simvastatin, fluvastatin and
pravastatin were obtained from commercial source. Simvastatin in lactone form was
activated by dissolving in ethanol and treatment at 50°C for 2 hours with 0.1 M NaOH.
Then, the pH was adjusted to 7.0 with HCl. The stock solutions of simvastatin, fluvastatin
and pravastatin were stored at a concentration of 10 mM at –20°C. Mevalonic acid lactone,
farnesyl pyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) were obtained
66
from Sigma (St. Louis, MO, USA). To obtain the active mevalonate salt, 13 mg of
mevalonic acid lactone was mixed with 0.1 M NaOH (2 hours, 50°C) and the pH was then
adjusted to 7.4. Farnesyltransferase inhibitor-277 (FTI-277) and geranylgeranyltransferase
inhibitor-286 (GGTI-286) were obtained from Calbiochem (San Diego, USA) and
dissolved in DMSO containing 10 mM dithiothreitol. Stock solutions were kept 1 week at
–70°C (FTI-277) or –20°C (GGTI-286). Monoclonal antibodies anti-VCAM-1 (anti-
CD106), and anti-E-selectin (anti-CD62E) were purchased from Serotec (Oxford, UK).
FITC-conjugated goat anti-mouse antibody, used as secondary antibody for FACS
analysis, was from Cappel Organon Technika (Durham NC, USA), and goat anti-mouse
IgG, conjugated with horseradish peroxidase (HRP) used for the ELISA method, was from
Bio-Rad Laboratories (Hercules CA, USA). O-phenylenediamine (OPD) tablet used as
substrate for bound HRP was obtained from Sigma. Protein A-Sepharose CL-4B was
purchased from Amersham Pharmacia Biotech AB. Endotoxin levels in the statin solutions
and IgG preparations were measured using the Limulus Amebocyte Lysate Endochrome
Assay (Charles River Laboratories, Charleston SC, USA). Bicinchoninic acid (BCA)
protein assay reagent for evaluating IgG content in the purified patient fractions was
obtained from Pierce Europe BV, Oud-Beijerland, The Netherlands.
Cell cultures
Human umbilical vascular endothelial cells (HUVEC)
HUVEC were isolated from collagenase-perfused umbilical cord veins as previously
described (Jaffe et al, 1973; Galve-de Rochemonteix et al, 2000). Briefly, the veins were
rinsed with Krebs-Ringer bicarbonate buffer (120 mM NaCl, 4.75 mM KCl, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3, 5 mM glucose, pH7.4) to
remove the red blood cells and incubated for 10 minutes at 37°C with 1 mg/ml collagenase
(CLS type 1, Worthington Biochemical, Lakewood NJ, USA) in Krebs-Ringer bicarbonate
buffer with 25 mM HEPES. Cells were collected by flushing the vein with 50 ml of RPMI
1640 supplemented with 5 % foetal calf serum (FCS) (Seromed Biochrom, Berlin,
Germany). After centrifugation (10 minutes, 1200 rpm), cells were cultured in Petri dishes
coated with 0.1 % gelatin at 37°C in a humidified atmosphere containing 5 % CO2. The
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culture medium was RPMI 1640 supplemented with 10 % FCS, 15 µg/ml EC growth
supplement (Upstate Biotechnology, Lake Placid NY, USA), 10 mM HEPES, 90 µg/ml
heparin (Boehringer Ingelheim, Germany), 100 IU/ml penicillin and 100 µg/ml
streptomycin (Gibco BRL-Life Technologies, Rockville MD, USA). After reaching
confluence, HUVEC were harvested with trypsin-EDTA, splited 1:2 and cultured in tissue-
culture dishes coated with gelatin. The cells were used at passages two to four for all
experiments.
Human saphenous vein cells (HSVEC)
HSVEC were isolated by collagenase treatment and cultured in gelatin coated dishes as
previously described (Kwak et al, 2000). Cells were maintained in medium 199 (Gibco
BRL-Life Technologies, Rockville MD, USA) supplemented with 100 IU/ml penicillin
and 100 µg/ml streptomycin (Gibco BRL-Life Technologies, Rockville MD, USA), 10%
foetal calf serum (FCS) (Seromed Biochrom, Berlin, Germany), 100 µg/ml heparin
(Boehringer Ingelheim, Germany), 15 µg/ml EC growth supplement (Upstate
Biotechnology, Lake Placid NY, USA), and 25 mM HEPES.
Methods
Purification of patient IgG
Patients sera and sera from normal subjects were purified by protein A-Sepharose CL-4B
affinity chromatography. The binding of IgG was performed using 0.1 M and 0.01 M Tris
buffer, pH 8.0 as a binding buffer. The available binding capacity was 20 mg human IgG
per ml of drained gel and the binding efficiency was approximately 90%. IgG were
thereafter recovered by acid elution with 0.1 M glycine HCl buffer pH 3.0. The protein
content of the eluted fractions was evaluated by BCA (bicinchonic acid) protein assay
reagent. The purified IgG fractions were found to have bacterial lipopolysaccharide < 0.06
ng / ml as determined by Limulus Amebocyte Lysate Endochrome Assay.
Analysis of adhesion molecule expression on EC by flow cytometry (FACS)
HUVEC and HSVEC were grown in 24-well plates. After confluence, the cells were
incubated in complete medium overnight with different concentrations of simvastatin (0.1 -
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5 µM), fluvastatin (0.1 - 15 µM) or pravastatin (5 - 15 µM) with or without mevalonate
(400 µM), GGPP (15 µM) or FPP (15 µM). Then, the cells were stimulated with TNF-α
(10 ng/ml) or bacterial lipopolysaccharide (20 ng/ml) for a period of 4 hours to measure
the effect on expression of E-selectin, and for 6 hours to measure the VCAM-1 expression.
When the cells were stimulated with purified APLA (0.5 mg/ml), overnight preincubation
with these antibodies in complete medium with 20 % FBS and without heparin was
performed. For negative controls cells were incubated with medium alone and normal
human serum IgG (0.5 mg/ml), respectively. Thereafter, the cells were washed in RPMI
and incubated for 1 hour at 4°C with primary mouse monoclonal antibody (anti-E-selectin,
anti-VCAM-1) at 10 µg/ml in PBS (Gibco, BRL-Life Technologies, U.K.), 5 % FCS, 0.02
% sodium azide. Cells were washed in PBS-FCS-sodium azide and incubated for 1 hour at
4°C with the secondary antibody, polyclonal FITC-conjugated goat anti-mouse antibody,
dissolved in PBS/FCS/sodium azide. Cells were washed in PBS-sodium azide, harvested
with trypsin-EDTA and, after centrifugation at 800 g for 5 minutes, fixed in 2.5 %
formaldehyde, 2 % glucose, 0.02 % sodium azide in PBS. Propidium iodide (10 µl of 50
µg/ml) was added to each sample. Cell fluorescence was analysed in a Becton Dickinson
FACScan flow cytometer (San Jose CA, USA). A total of 10’000 viable cells were
analysed per experimental sample. Data were analysed using the CELLQUEST software
(Becton Dickinson). The same experiments were performed with HUVEC incubated for 48
hours with GGTI-286 (10 µM) or FTI-277 (0.5- 2.5 µM). Fresh GGTI-286 or FTI-277
solutions were added after 24 hours. The concentration of GGTI-286 (10 µM) was five-
fold higher than its IC50 (2 µM) for the inhibition of geranylgeranyltransferase; the
concentration of FTI-277 (2.5 µM) was twenty five-fold higher than its IC50 (0.1 µM) for
the inhibition of farnesyltransferase and about twenty five fold lower than its IC50 (50 µM)
for the inhibition of gerenalygeranyltransferase (information provided by Calbiochem, San
Diego, USA). After the preincubation, cells were stimulated with TNF-α (10 ng/ml).
Cell Enzyme Linked Immunosorbent Assay (ELISA)
A modified ELISA was used to measure E-selectin and VCAM-1 content at the cell
surface. HUVEC and HSVEC were grown in 96-well coated plates and exposed to
simvastatin with or without mevalonate at same concentrations and incubation times as
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described for FACS analysis. After 4-6 hours incubation with TNF-α (10 ng/ml), cells
were washed 3 times with RPMI containing 2.5 % FCS and fixed in 4 % paraformaldehyde
for 15 minutes. After 3 washes with RPMI/FCS, cells were incubated for 1 h at room
temperature with primary mouse antibody (anti-E-selectin, anti-VCAM-1), diluted 1:1000
in RPMI/FCS. After 3 washes in RPMI / FCS and 1 wash in PBS, cells were incubated
with secondary antibody, goat anti-mouse IgG-horseradish peroxidase (HRP)-conjugated,
diluted 1:4000 in RPMI / FCS. After 1-hour incubation at room temperature, the wells
were washed 4 times in RPMI/FCS and once in PBS. Then 100 µl of 1 mg/ml o-
phenylenediamine dihydrochloride (OPD) solution was added and after 10 minutes
incubation at room temperature, the color development was stopped by addition of 50 µl of
3M H2SO4. The absorbance was read at 490 nm with an ELISA reader.
Statistical analysis
For ELISA assays, the effect of simvastatin on adhesion molecules expression was
analyzed with Kruskal-Wallis ANOVA and its reversal by mevalonate with Mann&Witney
test.
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II. RESULTS
Induction of E-selectin and VCAM-1 expression by IgG from patients with APS
In preliminary experiments we tested the ability of purified IgG from 13 patients with APS
to activate HUVEC. IgG derived from 6 patients with APS were found to induce a
proadhesive phenotype on HUVEC. We investigated the induction of adhesion molecule
expression by these APLA. As seen in Figure 13, HUVEC incubated for 24 hours with
purified patient IgG induced a moderate increase in VCAM-1 expression as measured by
flow cytometry analysis. Adhesion molecule expression of TNF-α stimulated cells was
defined as 100% cell activation. The APLA-induced VCAM-1 expression varied between
30% - 60% when compared with TNF-α. The induction of an adhesive phenotype on
endothelial cell by APLA was not attributable to contaminating endotoxin as all IgG
preparations had levels of endotoxin below 0.06 ng/ml as measured by the Limulus lysate
assay. Incubation of HUVEC with IgG derived from 6 healthy donors had no effect on
expression of VCAM-1 and E-selectin when compared with control non-treated cells.
Mean values (n=3) for E-selectin expression were 6.7 ± 3 and for VCAM-1 8.4 ± 1
expressed by cells treated with IgG from healthy donors. In the nontreated cells these
values were 6.3 ± 2.2 and 8.2 ± 2.2, respectively.
Effect of statins on the expression of E-selectin and VCAM-1 on EC
Effect of statins on TNF-α activated EC
1A) Simvastatin effect on HUVEC
ELISA method
First we investigated the effect of statins on the stimulation of HUVEC with TNF-α.
Compared to cells without TNF-α, in TNF-α treated HUVEC we observed a six fold
increase in E-selectin expression by cell-based ELISA. Pre-treatment of the cells with
different concentrations of simvastatin resulted in a dose dependent increase in their
response to TNF-α (Table 9). At concentrations of 1 to 2.5 µM of simvastatin, as
compared to non-pretreated cells, a 80% (p<0.001) and a 40% (p<0.001) increase were
observed for E-selectin and VCAM-1 expression, respectively. At higher simvastatatin
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concentrations, cell detachment and cell death were frequently observed. Addition of 400
µM mevalonate to the preincubation solution reversed the effect of simvastatin.
Flow cytometry analysis
We investigated E-selectin and VCAM-1 expression by flow cytometry analysis as well.
Figure 14A shows that after TNF-α stimulation the expression of E-selectin was strongly
increased. Strikingly, a very heterogeneous response was observed, a majority of cells
showing a high level of E-selectin expression and a minority a lower expression. A similar
heterogeneous response was observed when ten-fold higher TNF-α concentrations (100
ng/ml) were used (data not shown). This implies that the suboptimal response in some cells
was not due to insufficient TNF-α concentrations. For the remainder of our work, a TNF-α
concentration of 10 ng/ml was used. In cells pre-treated with simvastatin and then with
TNF-α, almost all cells exhibited a high level of E-selectin expression. The effect of
simvastatin was reversed by pre-treatment with mevalonate (Figure 14B).
1B) Simvastatin effect on saphenous vein EC
Figure 15 shows that simvastatin pre-treatment had similar effects on VCAM-1 expression
in response to TNF-α both in HUVEC (A, B) and human saphenous vein EC (C). Table 10
summarises the mean (± SD, N= 10 independent experiments) fluorescence values
obtained by flow cytometry for TNF-α treated HUVEC. It shows that E-selectin
expression varied between 150% and 223% in simvastatin pre-treated HUVEC as
compared to non-pre-treated cells. VCAM-1 expression was 118% to 156% in the
simvastatin pre-treated cells as compared to non-pre-treated cells. Addition of 400 µM
mevalonate to the preincubation solution reversed the effect of simvastatin.
2. Fluvastatin effect on EC
Similar results were obtained by flow cytometry with HUVEC preincubated with
fluvastatin and stimulated with TNF-α (Figure 16A). At fluvastatin concentrations of 5
µM, E-selectin expression was increased (210% in one experiment, 321% in another one)
and VCAM-1 expression was increased 143% and 160% (n=2) when compared with
HUVEC treated with TNF-α alone. This effect was completely reversed by mevalonate
(Figure 16B).
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3. Pravastatin effect on EC
Preincubation of HUVEC with pravastatin, a hydrophilic statin, similarly augmented the
TNF-α response of these cells. At pravastatin concentrations of 10 µM and 15 µM, a
further 28 % increase in E-selectin expression was observed by flow cytometry analysis in
TNF-α treated HUVEC and this effect was completely reversed by mevalonate (Figure
17). Mean values (n=6) for E-selectin expression were expressed as a percentage of mean
value of non-statin pre-treated, TNF-α stimulated cells. The mean percentage values were:
cells treated with TNF-α alone: 100 % (control); pravastatin pre-treated and TNF-α
stimulated cells: 128 % ± 13 % (p < 0.02 vs control); cells treated with pravastatin,
mevalonate and TNF: 97 % ± 11 %. Since the pravastatin effect was weaker than
simvastatin, we focused on simvastatin and fluvastatin for the remainder of our work.
Effect of statins on bacterial lipopolysaccharide activated EC
Simvastatin pre-treatment similarly increased E-selectin expression in cells stimulated with
20 µg/ml bacterial lipopolysaccharide (Figure 18).
Effect of statins on APLA activated EC
We next performed flow cytometry analysis to study the effects of simvastatin and
fluvastatin on HUVEC, activated with patient derived APLA. Contrary to what could be
expected from clinical data, we observed an increase in adhesion molecule expression
(Figure 19A) and this effect was completely reversed by mevalonate (Figure 19B). Figure
20 summarises the mean fluorescence values obtained by flow cytometry for HUVEC
treated with APLA. It shows that APLA induced a 1.5 to 6 fold increase in E-selectin
expression when compared to control (non-treated) cells. Fluvastatin pre-treatment gave a
further 1.5- 2 fold increase in E-selectin as compared to non-pre-treated HUVEC. VCAM-
1 expression was between 3 and 8 fold higher in APLA-activated cells as compared to non-
activated cells and pre-treatment with fluvastatin led to another 2 to five fold increase in
VCAM-1 expression as compared to non-pre-treated cells. Addition of 400 µM
mevalonate to the preincubation solution reversed the effect of fluvastatin. These results
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suggest that statins induce an additional increase of VCAM-1 and E-selectin in HUVEC
activated by human affinity purified IgG APLA.
In the absence of stimulation of HUVEC by TNF-α, bacterial lipopolysaccharide or
APLA, pretreatment with simvastatin and fluvastatin had no effect on the expression of E-
selectin (mean fluorescence 7.5 ± 2 vs 5.5 ± 2 in control cells; n= 6) and VCAM-1 (8 ± 3
vs 6 ± 2). Also, mevalonate pre-treatment had no effect on the basal expression of E-
selectin (mean fluorescence 10 ± 3 vs 5.5 ± 2; n= 6) and VCAM-1 (12 ± 3 vs 6 ± 2, n=7).
Statin effects on APLA-stimulated HUVEC were comparable with statin effects on TNF-α
and bacterial lipopolysaccharide activated HUVEC.
The effect of statins on adhesion molecule expression is reversed by isoprenoid
intermediates
By inhibiting L-mevalonic acid synthesis, statins reduce the synthesis of intermediates
from the mevalonate pathway. In Figures 14B, 16B and 20 as well as in Tables 9 and 10,
we have shown that mevalonate reverses the increasing effect of simvastatin and
fluvastatin on adhesion molecule expression to values comparable to TNF-α and APLA
alone. This demonstrates that the statin effect is due to inhibition of HMG-CoA reductase.
Mevalonate is an essential intermediate not only for cholesterol biosynthesis but also for
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), which are
important lipid attachments for the post-translational modification of proteins. We
investigated the effect of GGPP and FPP on simvastatin mediated TNF-α-induced E-
selectin overexpression. GGPP (15 µM) completely reversed the increasing effect of
simvastatin (Figure 21) and fluvastatin (Figure 22) while with FPP (15 µM), only a partial
reversal was achieved. With higher doses of FPP we did not obtain a complete reversal
effect (data not shown). Mean values (n=3) for E-selectin expression were expressed as a
percentage of mean value of non-pre-treated, TNF-α stimulated cells as follows: TNF-α
stimulated cells 100%, simvastatin pre-treated cells 186% ± 40 %, simvastatin and GGPP
preincubated cells 94 % ± 8 % and finally simvastatin and FPP preincubated cells 125 % ±
11 %. For HUVEC preincubated with 5 µM fluvastatin the mean value (n=2) for E-selectin
expression in percentage was as follow: TNF-α stimulated cells 100%, fluvastatin pre-
treated cells 200% ± 11%, fluvastatin and GGPP preincubated cells 110% ± 20% and
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fluvastatin and FPP preincubated cells 150% ± 5%. These results suggest that statin effect
is due to the inhibition of protein geranylgeranylation.
Similar results were obtained when HUVEC were activated by APLA. The overnight
preincubation with GGPP completely reversed the potentiating effect of fluvastatin on E-
selectin and VCAM-1 (Figure 20). These results demonstrated that geranylgeranylation
might be involved in the potentiating effect of statins on TNF-α and APLA-induced
adhesion molecule expression.
Inhibition of protein geranylgeranylation, but not protein farnesylation mimicks the
effect of statins
The farnesylation or geranylgeranylation of proteins are catalysed by farnesyltransferase
(FTase) or geranylgeranyltransferase (GGTase), respectively. To study the role of these
enzymes, we investigated whether FTI-277 (2.5 µM) and GGTI-286 (10 µM), selective
inhibitors of FTase and GGTase respectively, could mimick the effect of simvastatin.
Pre-treatment of HUVEC with GGTI-286 caused a significant increase in TNF-α-
stimulated E-selectin expression, comparable to the effect of simvastatin (Figure 23A). In
contrast, FTI-277 pre-treatment had no effect on E-selectin expression in TNF-α treated
cells (Figure 23B). These results were confirmed on APLA-activated HUVEC where the
potentiating effect of fluvastatin on VCAM-1 and E-selectin was mimicked by GGTI-286
(Figure 20). This effect on protein prenylation indicates that inhibition of protein
geranylgeranylation but not farnesylation increase adhesion molecule expression in TNF-α
and APLA-stimulated endothelial cells.
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PART IV: DISCUSSION and CONCLUSION
Interaction of leukocytes with endothelial cells is an important part of the inflammatory
pathway leading to vascular disease (Ikeda et al, 1998; Cines et al, 1998). Several studies
have shown that APS, a hypercoagulable state associated with high titers of circulating
APLA, may be the result of an APLA-dependent endothelial cell activation. This may lead
to an enhanced expression of the adhesion molecules ICAM-1, VCAM-1 and E-selectin on
EC and consequently an increased monocyte adherence to EC (Simantov et al, 1995).
Indeed Pierangeli et al (1999) have demonstrated that upregulation of expression of
ICAM-1, VCAM-1 and E-selectin on EC by APLA correlated directly with an increased
adhesion of leukocytes to endothelium of mouse cremaster muscle (an indication of EC
activation in vivo) and with enhanced thrombosis. In another study, George et al (1998)
have shown that the upregulation of adhesion molecules by murine monoclonal anti-β 2GPI
antibodies correlated with foetal resorption in mice producing APLA. As additional
support for the hypothesis that APLA antibodies activate EC and may create an
hypercoagulable state in APS patients, Kaplanski et al (2000) demonstrated that the levels
of soluble ICAM-1 and VCAM-1 were significantly increased in the plasma of patients
with APS and recurrent thrombosis.
In our study we confirm that purified IgG from patients with APS are able to induce
VCAM-1 and E-selectin expression on HUVEC. Induction of an adhesive phenotype on
endothelial cell is not attributable to contaminating endotoxin since purified IgG from
healthy donors are not able to induce adhesion molecule expression and Limulus assays on
sample preparations were always negative. We can thus conclude that the effect of APLA
on EC is specific.
As the so-called pleiotropic "anti-inflammatory" effects of statins represent an attractive
mechanism for their beneficial clinical effects in addition to their well known cholesterol
lowering effects (Koh et al, 2000; Werner et al, 2002; Takemoto et al, 2001; Case et al,
2002), we examined whether the statins decrease the expression of adhesion molecules by
endothelial cells stimulated with APLA. We investigated the statin effects on the
expression of leukocyte adhesion molecules by HUVEC or saphenous vein stimulated first
by TNF-α and bacterial lipopolysaccharide, and next by IgG from APS patients.
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Contrary to what was expected, we consistently demonstrated that preincubation with
fluvastatin and simvastatin led to a moderate increase in the E-selectin and VCAM-1
response to TNF−α as well as bacterial lipopolysaccharide in HUVEC. This effect was
HMG-CoA-reductase dependent since it was reversed by mevalonate. Other studies have
investigated the effects of statins on adhesion molecule expression by HUVEC but the
results were quite divergent. Our results are in agreement with those of Sadeghi et al
(2000) and Schmidt et al (2002) who found a potentiating effect of simvastatin or
lovastatin on the cytokine-mediated increase in adhesion molecule expression by using
flow cytometry analysis or a cell-based ELISA methods. Our results are also comparable
with the data of Bernot et al (2003) who found that atorvastatin significantly enhanced
surface VCAM-1, ICAM-1, E-selectin and fractalkine in TNF−α activated HUVEC as
measured by flow cytometry and confocal microscopy.
Our findings, however, are in contradiction to the results of Meroni et al (2001) who
reported that fluvastatin and simvastatin decreased E-selectin and ICAM-1 response to
TNF-α and bacterial lipopolysaccharide measured using an ELISA method or with those
of Wagner et al (2002), who reported an inhibition of VCAM-1 expression by atorvastatin
when EC were stimulated with TNF-α and interferon-γ. Finally, Rasmussen et al (2001)
reported that inhibition of HMGR in EC attenuated VCAM-1 expression, but increased E-
selectin expression, after stimulation with cytokines.
Our data also show that simvastatin has a similar effect on endothelial cells from
saphenous vein as that on HUVEC, thus indicating the simvastatin effects of adhesion
molecule-induced expression are similar in different types of endothelial cells.
By flow cytometry, we observed that the E-selectin response to TNF-α or bacterial
lipopolysaccharide was heterogeneous, with part of the cytokine-stimulated cells
expressing a high level of E-selectin and part of the cytokine-stimulated cells expressing an
intermediate level of E-selectin. After pre-treatment of the cells with simvastatin,
fluvastatin or the geranylgeranyl-transferase inhibitor GGTI-286, the large majority of the
cytokine-stimulated cells exhibited a strong E-selectin response that was comparable to
that of the high responders to TNF-α in the control group. This suggests that simvastatin,
fluvastatin or GGTI-286 act on a subgroup of cells that respond poorly to TNF-α. Because
an increase of the TNF-α concentration by ten folds did not further increase the adhesion
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molecule response, we can conclude that the poor response of part of the control cells was
not due to suboptimal TNF-α concentrations.
We next investigated the statin effects on endothelial cell adhesive properties induced by
APLA. We demonstrated that stimulation of HUVEC with patients’ APLA led to a
moderate increase of the surface adhesion molecule levels. Again, contrary to what could
eventually be expected from clinical data, preincubation of the cells with simvastatin or
fluvastatin led to an increase in the E-selectin and VCAM-1 response to APLA. Taken
together our results show that statins increase rather than decrease adhesion molecule
expression by APLA, TNF-α or bacterial lipopolysaccharide activated EC.
Statins block L-mevalonic acid synthesis and consequently its conversion into
farnesylpyrophosphate (FPP), which is a precursor for geranylgeranylpyrophosphate
(GGPP). Both FPP and GGPP are essential substrates for protein isoprenylation. This
posttranslational modification is required for the cellular localization and biological
function of small G-proteins such as Ras or Rho (Takemoto et al, 2001; Allal et al, 2000;
Matozaki et al, 2000). In EC, Ras translocation from the cytoplasm to the plasma
membrane is dependent on farnesylation whereas Rho translocation is dependent on
geranylgeranylation (Laufs et al, 1998a; Laufs et al, 1998b). Statins, by inhibiting Ras and
Rho isoprenylation, lead to the accumulation of inactive Ras and Rho in the cytoplasm.
Studies have shown that inhibition of Rho isoprenylation mediates some effects of statins
in vascular cells (Laufs et al, 1998a; Laufs et al, 1999). To determine which isoprenyl
group is involved in the statin effect on leukocyte adhesion molecule expression, we
determined whether FPP or GGPP could reverse the effects of statins. The enhancing
effect of simvastatin or fluvastatin on TNF-α-induced E-selectin expression was reversed
by GGPP and partially by FPP, indicating that the inhibition of protein isoprenylation, but
not of cholesterol synthesis, is associated with the effect of these statins. Accordingly,
statin effects on APLA-activated EC were reversed by GGPP as well. As FPP is a
precursor for GGPP, but GGPP cannot function as a precursor for FPP, our results suggest
that these statins act by inhibition of protein geranylgeranylation. These reversal effects of
GGPP and FPP have been also shown by Sadeghi et al (2000). They observed an inhibition
of IL-1-mediated adhesion molecule induction by direct G protein activator NAF and
proposed that geranylgeranylated G proteins might be involved in the cytokine-induced
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increase in adhesion molecule expression. Further support for the idea that the statin effect
is on protein geranylgeranylation and not protein farnesylation is provided by our results
which show that the geranylgeranyl transferase inhibitor (GGTI 286) mimicks the effect of
simvastatin or fluvastatin in TNF-α or APLA activated EC, whereas the farnesyl
transferase inhibitor FTI-277 had no such effect.
Taken together our results suggest that the enhancing effects of statins on cytokine-
mediated adhesion molecule be due to an inhibition of protein geranylgeranylation. A large
number of geranylgeranylated proteins are known. Most likely one (or more) of these
proteins downregulates the adhesion molecule response of EC to TNF-α and APLA. The
identification of such proteins may improve our understanding of the factors that modulate
the response of EC to inflammatory mediators.
Our data also indicate that the beneficial effect of statins observed in clinical studies is
probably not due to a suppression of the EC response to TNF-α, bacterial
lipopolysaccharide or APLA. Several studies have shown that statin treatment could
improve endothelial cell function in multiple ways, for example by decreasing the
synthesis of endothelin-1, by increasing the synthesis of eNOS or the capacity of these
cells to inhibit platelet adhesion and aggregation (Hernandez-Perera et al, 1998; Takemoto
et al, 2001; Sposito et al, 2002; Seeger et al, 2000; Kaneider et al, 2002). The complexities
of the anti-inflammatory effects of statins have been the subject of a recent review
emphasizing that statins have also HMG-CoA reductase-independent effects, for example
by a specific inhibition of lymphocyte-function-associated antigen 1 binding to ICAM-1
(Weitz-Schmidt et al, 2002).
Divergent results were also obtained when adhesion molecules were measured before and
after statin treatment. Indeed some studies demonstrated a reduction of ICAM-1 after
pravastatin (Blann et al, 2001) or fluvastatin (Romano et al, 2000) in hypercholesterolemic
patients. However several other studies (Hackman et al, 1996; Rauch et al, 2000; Koh et al,
2000; Sardo et al, 2001) were unable to find a decrease of different adhesion molecules.
Very recently, Jilma et al (2003) compared in a randomized trial the effects of three-month
treatment with standard doses of atorvastatin, simvastatin and pravastatin on plasma levels
of ICAM-1 and E-selectin in 75 hypercholesterolemic patients. None of the statins lowered
plasma adhesion molecules.
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At the present time, we can only speculate on the conflicting literature data on the effect of
statins on the response of EC to inflammatory agents and APLA. It is known that statins
inhibit farnesyl biosynthesis. Farnesyl is a precursor not only for cholesterol biosynthesis
but also for protein farnesylation and geranylgeranylation and, as a precursor for dolichol,
it is important for protein glycosylation. As an example there are already more than
hundred small GTP binding proteins that depend for their biological activity on a farnesyl
or geranylgeranyl anchor. Several of these small GTP binding proteins play key roles in
gene expression and cytoskeletal organization. It is possible that among the different
proteins that are affected by statins, some have a co-stimulatory effect on TNF-α and
APLA treated cells, whereas others have an inhibitory effect. The balance between the
stimulatory and inhibitory activities, and thus the effect of statin treatment, could depend
on subtle differences in cell culture conditions, timing of addition of agents, subendothelial
matrix or other experimental conditions.
In conclusion, our results show that statins potentiate the adhesive properties of endothelial
cells in response to APLA. Our findings suggest that a geranylgeranylated protein limits
the response of endothelial cells to APLA. The identification of this geranylgeranylated
factor may lead to novel approaches to control the inflammatory activation of endothelial
cells. Obviously these in vitro data do not exclude a possible favourable effect in vivo of
statins in a clinical trial. However, if such a benefit is shown in APS patients, this should
be explained by other mechanisms than by the inhibition of adhesion molecules by
endothelial cells.
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Figure 1. Structural representations of human blood plasma β2GPI revealing 
the extended chain of the five SCR domains. (A) Ribbon drawing of β2GPI
with consecutive domains labelled I-V. N-linked glycans, as well as the
position of the putative O-linked glycan, Thr130, are indicated by a ball-and-
stick model. The strands are shown in red and helices in green. (B) Topology
diagram of β2GPI. The central sheets of all five domains are labelled B2(-
B2)-B3-B4(-B5), the N- and C-terminal -sheets are labelled B1'-B2' and B4'-
B5', the -helix and the 3/10 helix are denoted A1 and A2 and numbers of
residues delimiting secondary structure elements are given. Disulfide bonds 
are indicated with dashed lines. The positions of N-glycosylation are given by 
hexagons; a diamond indicates the putative O-glycan. Horizontal dashed lines 
mark domain boundaries. (C) Ribbon representation of domain III of β2GPI
with labelled secondary structure elements. The two fully conserved  disulfide
bonds are shown in yellow. (D) Ribbon representation of domain V of β2GPI
with labelled secondary structure elements. The three disulfide bonds are 
indicated with yellow lines. The aberrant face, which contains the membrane-
binding site, is located on the right-hand side. 
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Figure 2. Approach to the diagnosis of LA. More information: Guidelines of the 
International Society of  Thrombosis and Haemostasis. Tests need to be repeated 
on 2 occasions, at least 6 weeks apart.
N:  normal, P: prolonged, C: correction, NC:  no correction
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Figure 3. Sites of action of the essays in the cascade 
PL: phospholipids, aPTT: PL:activated partial thromboplastin time, daPTT: 
diluteactivated partial thromboplastin time, KCT: kaolin clotting time, SCT: silica 
clotting time, DRVVT : dilute Russell’s viper venom time, TTI: tissue 
thromboplastin inhibition
Figure 4
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Figure 4. Coexistence or independent occurrence of  LA, ACA and VDRL 
antibodies in APS.
LA: lupus anticoagulant, ACA: anticardiolipin antibodies, VDRL: antibodies 
reacting with the Veneral Disease Research Laboratory reagent
Figure 5
Figure 5. Model of blood coagulation.
TF-VIIa: tissue factor-FVIIa complex, TFPI: tissue factor pathway inhibitor, APC: activated 
protein C, PS: protein S, T: thrombomodulin, TAFI: thrombin-activatable fibrinolysis inhibitor, t-
PA: tissue-type plasminogen activator. An uninterrupted line indicates activation, while an
interrupted line indicates inactivation. The uninterrupted line between Xa and TFPI indicates that 
FXa has to form a complex with TFPI, and that this complex then inhibits TF-FVIIa. 
J Thromb Haemost 2003; 1: 1566
Figure 6
Figure 6. Schematic representation of blood coagulation and the protein C anticoagulant system. 
Section A demonstrates an incomplete scheme of blood coagulation reactions together with the 
balancing anticoagulant reactions of the protein C pathway. In section B (I–IV), the membrane-
bound molecular events of selected reactions are shown in cartoon-like fashion. I: activation of
prothrombin (PT) to thrombin (T), a reaction that also generates the F1.2 prothrombin fragment. 
II: thrombomodulin (TM) and the endothelial protein C receptor (EPCR) are proteins that span 
the membrane. The role of EPCR is not fully understood, but it has been shown to be able to 
bind the Gla-domain of protein C, which results in stimulation of protein C activation. III: the 
degradation of FVa by APC is enhanced by protein S (PS). IV: degradation of FVIIIa by APC is 
stimulated by the synergistic cofactor activity of protein S and factor V. The large B domain that 
protrudes from the triangularly arranged A1–A3 domains of FV is in the linear sequence located 
between A2 and A3 domains.
J Thromb Haemost 2003; 1: 1525
Figure 7
Figure 7. Regulation of blood clotting. 
Inhibitors that control coagulation are shown in gray boxes above the complex or factor they 
regulate (AT: antithrombin, ZPI: protein Z-dependent protease inhibitor, PCI: protein C
inhibitor). Top panel: FVIIa binds to tissue factor (TF) to activate FX, generating
FXa. FXa then binds to FVa. The complex of FXa–FV converts prothrombin to thrombin (T).
Thrombin can then either bind to TM or carry out procoagulant reactions like fibrin
formation or platelet activation. When bound to TM, thrombin can activate protein C (PC) to
APC. This process is enhanced when protein C is bound to the EPCR. APC bound to EPCR
cleaves substrates other than FVa. APC dissociates from EPCR and can then interact with 
protein S to inactivate FVa. Bottom panel: The FIXa–FVIIIa complex is inactivated by APC. 
In this case, FV participates with APC and protein S in the inactivation of FVIIIa. For
simplicity, the activation of FVII, FV and FVIII are not shown.
J Thromb Haemost 2003; 1: 1343
Figure 8
Figure 8. Protein C Pathway
Protein C activation takes place by way of interaction between the thrombomodulin–
thrombin complex and the endothelial protein C receptor. Activated protein C,
together with its cofactor, protein S, inactivates factors V and VIII to provide 
negative feedback to the generation of thrombin. Complex 1 comprises TF and 
coagulation factors VII, IX and X; complex 2 comprises factors IX and X and
cofactor VIII; and complex 3 comprises factor X, prothrombin and cofactor V.
N Engi J Med 2001; 345: 409
Figure 9
Figure 9. Structural formulas of statins and their site of action in the cholesterol 
biosynthetic pathway
HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A.
Am J Cardiol 1998; 82: 3
Figure 10
Figure 10. The mevalonic pathway and possible effects of hydrophilic and
hydrophobic statins. In liver cells hydrophilic statins gain access by a receptor 
mediated process
Lancet 2002; 359: 2195
Figure 11
Figure 11. Pathway for cholesterol biosynthesis. Inhibition of HMG-CoA 
reductase by statins decreases the synthesis of isoprenoids and cholesterol 
Trends Cardiovasc Med 2000; 10: 143
Figure 12a
Figure 12a. Effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibition (statins) on biosynthesis of cholesterol and
isoprenoids. Many pleiotropic effects of statins are thought to be 
mediated by a reduction in protein isoprenylation
Am J Cardiol 2003; 20: 91
Figure 12b
Figure 12b. Inhibitory effects of statins on small G-proteins.
Isoprenylation is a necessary step in activation of members of the Rho
and Ras families. Statins decrease the synthesis of isoprenoid 
intermediates, thereby preventing activation. 
CoA: coenzyme A; GDP:  guanosine diphosphate; GTP: guanosine 
triphosphate; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A
Am J Cardiol 2003; 20: 91
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Figure 13. Flow cytometry analysis of APLA-induced VCAM-1 expression
Confluent HUVEC were incubated with purified patient APLA (500 µg/ml) or 
TNF-α 10 ng/ml for 24 hours and surface VCAM-1 adhesion molecules were 
measured by  flow cytometry analysis. Mean value for VCAM-1 expression 
induced by TNF-α was taken for 100%. The results were expressed as a
percentage of mean value of TNF-α 10 ng/ml treated cells.
Table 9
Simvastatin
(µM)
E-selectin
Mean +/- S.D
VCAM-1
Mean +/- S.D
Simvastatin Simvastatin with
400 µM mevalonate
Simvastatin Simvastatin with
400 µM mevalonate
0 100* 102 ± 3§ 100* 105 ± 3§
0.1 150 ± 21* 119 ± 15§ 118 ± 23*  89 ± 13§
0.5 178 ± 20*  96 ± 10§ 140 ± 60*  86 ± 20§
1 223 ± 36* 125 ± 10§ 154 ± 62* 117 ± 38§
2.5 186 ± 40* 109 ± 10§ 156 ± 64* 119 ± 55§
Table 9. Cell ELISA analysis of simvastatin effect on TNF-α induced E-selectin
and VCAM-1 expression
Mean values (n=5) for each simvastatin concentration were expressed as a
percentage of mean O.D. value of TNF-α 10 ng/ml treated cells without 
simvastatin. * P<0.001 for E-selectin and VCAM-1 expression mediated by 
simvastatin. § P<0.001 for mevalonate
Table 10
Simvastatin
(µM)
E-selectin
Mean +/- S.D
VCAM-1
Mean +/- S.D
Simvastatin Simvastatin with
400 µM mevalonate
Simvastatin Simvastatin with
400 µM mevalonate
0 100 102 ± 3 100 105 ± 3
0.1 150 ± 21 119 ± 15 118 ± 23  89 ± 13
0.5 178 ± 20  96 ± 10 140 ± 60  86 ± 20
1 223 ± 36 125 ± 10 154 ± 62 117 ± 38
2.5 186 ± 40 109 ± 10 156 ± 64 119 ± 55
Table 10. Flow cytometry analysis of simvastatin effect on TNF-α induced E-
selectin and VCAM-1 expression.
Mean values (n=10) for each simvastatin concentration were expressed as a
percentage of mean value of TNF-α 10 ng/ml treated cells without simvastatin. 
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Figure 14. The effect of simvastatin on TNF-α-induced E-selectin expression (A)
and its reversal by pretreatment with mevalonate (B). Confluent HUVEC were
pretreated overnight with 2.5 µM simvastatin (A) or 2.5 µM simvastatin with 400
µM mevalonate (B). TNF-α (10 ng/ml) was added to the medium for 4 hours and
E-selectin expression at the cell surface was measured by flow cytometry analysis
as described in the Methods section. I represents E-selectin expression in control
HUVEC; II represents E-selectin expression after TNF-α treatment; III represents
TNF-α induced E-selectin expression after an overnight  preincubation with
simvastatin; and IV represents the TNF-α induced E-selectin expression after an
overnight preincubation with simvastatin and mevalonate.
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Figure 15
Figure 15. The effect of simvastatin on 
TNF-α-induced VCAM-1 expression 
on HUVEC (A), or on human 
saphenous vein EC (C), and the 
reversal of simvastatin effect by 
mevalonate on HUVEC (B). Confluent 
HUVEC were pretreated overnight 
with 1 µM simvastatin (A), or 1 µM 
simvastatin with 400 µM mevalonate 
(B). TNF-α (10 ng/ml) was added to 
the medium for 6 hours and VCAM-1 
expression at the cell surface was 
measured by flow cytometry analysis. 
The same experiment was performed 
with human saphenous vein EC (C). I 
represents VCAM-1 expression in 
control HUVEC/saphenous vein; II 
represents VCAM-1 expression after 
TNF-α treatment; III represents TNF-
α induced VCAM-1 expression after 
an overnight  preincubation with 
simvastatin; and IV represents 
VCAM-1 expression after TNF-α and 
an overnight preincubation with 
simvastatin and mevalonate.
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Figure 16. The effect of fluvastatin on TNF-α mediated E-selectin expression. 
Confluent HUVEC were pretreated overnight with 5 µM fluvastatin (A), 5 µM
fluvastatin with 400 µM mevalonate (B). TNF-α (10 ng/ml) was added to the 
medium for 4 hours and surface E-selectin adhesion molecules were measured by 
flow cytometry analysis as described in the Methods section. I represents E-selectin
expression in control HUVEC, II represents E-selectin expression after TNF-α, III-
E-selectin expression of fluvastatin pretreated TNF-α stimulated cells, and 
IVrepresents E-selectin expression after overnight preincubation with fluvastatin +
mevalonate and stimulation with TNF-α.
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Figure 17. The effect of pravastatin on TNF-α mediated E-selectin expression. 
Confluent HUVEC were pretreated overnight with 15 µM pravastatin. TNF-α (10
ng/ml) was added to the medium for 4 hours and surface E-selectin adhesion 
molecules were measured by flow cytometry analysis as described in the Methods 
section. I represents E-selectin expression in control HUVEC, II represents E-
selectin expression after TNF-α, III- E-selectin expression of pravastatin pretreated
TNF-α stimulated cells
Figure 18
I
II
III
Figure 18. The effect of simvastatin on LPS mediated E-selectin expression. 
Confluent HUVEC were pretreated overnight with 2.5 µM simvastatin. LPS (20 
ng/ml) was added to the medium for 4 hours and surface E-selectin adhesion 
molecules were measured by flow cytometry analysis. I represents E-selectin
expression in control HUVEC, II represents E-selectin expression after LPS, III- E-
selectin expression of simvastatin pretreated LPS stimulated cells.
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Figure 19. The effect of fluvastatin on APLA-induced VCAM-1 expression.
Confluent HUVEC were pretreated overnight with 5 µM fluvastatin. Purified patient 
APLA (500 µg/ml) was added to the medium for 24 hours and surface VCAM-1adhesion 
molecules were measured by flow cytometry analysis. I represents VCAM-1 expression 
in control HUVEC, II represents VCAM-1 expression after APLA incubation, III 
represents VCAM-1 expression of fluvastatin pretreated APLA stimulated cells (the 
figure represents the results with APLA obtained from serum of patient 1).
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Figure 20
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Figure 20. The effect of fluvastatin and GGTI-286 on APLA-induced VCAM-1 
expression and its reversal by mevalonate and GGPP. Confluent HUVEC were 
pretreated overnight with 5 µM fluvastatin, or 5 µM fluvastatin with 400 µM 
mevalonate, or 5 µM fluvastatin with 15 µM GGPP, or 10 µM GGTI-286 . Purified 
patient APLA (500 µg/ml) were added to the medium for 24 hours and surface 
VCAM-1 adhesion molecules were measured by flow cytometry analysis.
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Figure 21. Inhibition by the isoprenoid
intermediates farnesyl pyrophosphate
(FPP) and geranylgeranylpyrophosphate
(GGPP) of the potentiating effect of
simvastatin on TNF-α induced E-selectin
expression. Fig. 21A shows the effect of
simvastatin on TNF-α induced E-selectin
expression, Fig. 21B shows the effect of
GGPP on simvastatin pretreated and
TNF-α stimulated HUVEC and Fig. 21C
shows the effect of FPP on simvastatin
pretreated and TNF-α stimulated
HUVEC, compared to the effect of
GGPP. Confluent HUVEC were
pretreated overnight with 2.5 µM
simvastatin alone, or in the presence of
15 µM GGPP or 15 µM FPP. Cells were
incubated with TNF-α (10 ng/ml) for 4
hours and E-selectin expression was
measured by flow cytometry analysis. I
represents E-selectin expression on
control HUVEC; II represents E-selectin
expression after TNF-α stimulation; III
represents expression of E-selectin on
simvastatin pretreated TNF-α stimulated
cells; V represents the TNF-α induced
expression of E-selectin after an
overnight preincubation with simvastatin
+ GGPP; and VI represents the TNF-α
induced E-selectin expression after
preincubation with simvastatin + FPP.
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Figure 22. The effect of fluvastatin on TNF-α mediated E-selectin expression 
(A) and its reversal by GGPP or FPP (B). Confluent HUVEC were pretreated
overnight with 5 µM fluvastatin (A),  or 5 µM fluvastatin with 15 mM GGPP or 
15 mM FPP (B). TNF-α (10 ng/ml) was added to the medium for 4 hours and E-
selectin expression on the cell surface was measured by flow cytometry analysis 
as described in the Methods section. I represents E-selectin expression on 
control HUVEC; II represents E-selectin expression after TNF-α treatment; III 
represents the E-selectin expression of fluvastatin pretreated and TNF-α
stimulated cells; IV represents the TNF-α induced expression of E-selectin after 
an overnight preincubation with fluvastatin + GGPP, and V represents TNF-α
induced E-selectin expression after an overnight preincubation with fluvastatin + 
FPP. 
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Figure 23. Effect of inhibitors of the farnesyltransferase inhibitor-277 (FTI-277) or 
the geranylgeranyltransferase inhibitor-286 (GGTI-286) on TNF-α induced adhesion 
molecules expression. Fig. 23A demonstrates the effect of GGTI-286 on TNF-α
induced E-selectin expression, and Fig. 23B shows the effect of FTI-277 on TNF-α
induced E-selectin expression, compared with the effect of GGTI-286. Confluent 
HUVEC were pretreated for 48 hours with 2.5 µM simvastatin, or with 10 µM 
GGTI-286, or with 2.5 µM FTI-277 added to the complete medium. The medium 
was changed and fresh inhibitors were added every 24 hours. Then, TNF-α (10 
ng/ml) was added to the medium for 4 hours and E-selectin expression was 
measured by flow cytometry analysis. I represents E-selectin expression on control 
HUVEC; II represents E-selectin expression after TNF-α treatment; III represents E-
selectin expression after overnight preincubation with simvastatin and consequent 
stimulation with TNF-α; IV represents TNF-α induced E-selectin expression after 
overnight preincubation with GGTI-286; and V represents TNF-α induced E-selectin 
after overnight preincubation with FTI-277.
Dimitrova et al. J Thromb Haemost, in press 2003
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